<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on November
1, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Onconetix, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>83-2262816</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial <BR>
Classification Code Number)</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer <BR>
Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>201 E. Fifth Street, Suite 1900<BR>
Cincinnati, Ohio 45202<BR>
Telephone: (513) 620-4101<BR>
</B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Karina M. Fedasz<BR>
Interim Chief Financial Officer<BR>
201 E. Fifth Street, Suite 1900<BR>
Cincinnati, Ohio 45202<BR>
Telephone: (513) 620-4101<BR>
</B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>with copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Barry I. Grossman, Esq.<BR>
Jessica Yuan, Esq.<BR>
Ellenoff Grossman &amp; Schole LLP<BR>
1345 Avenue of the Americas<BR>
New York, NY 10105<BR>
Phone: (212) 370-1300<BR>
Fax: (212) 370-7889</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Approximate date of commencement
of proposed sale to the public: </B>From time to time after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section
8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities
and Exchange Commission acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B></B>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Red"><B>The information in
this prospectus is not complete and may be changed. The selling stockholder named in this prospectus may not sell these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these
securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%"><FONT STYLE="font-size: 10pt; color: Red"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; width: 2%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 32%"><FONT STYLE="font-size: 10pt; color: Red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; width: 2%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 32%"><FONT STYLE="font-size: 10pt; color: Red"><B>DATED <FONT STYLE="text-transform: uppercase">NOVEMBER
1</FONT>, 2024</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6,250,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to
the offer and sale from time to time by Keystone Capital Partners, LLC (&ldquo;Keystone&rdquo; or the &ldquo;Selling Stockholder&rdquo;)
of up to 6,250,000 shares of common stock of Onconetix, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;Onconetix&rdquo;), par value $0.00001 per share (the &ldquo;Common Stock&rdquo;), that have been or may be issued by us to Keystone
pursuant to that certain Common Stock ELOC Purchase Agreement, dated as of October 2, 2024, by and between us and Keystone (the &ldquo;ELOC
Purchase Agreement&rdquo;), establishing an equity line of credit. Such shares of our Common Stock include up to 6,250,000 shares of Common
Stock (assuming the shares to be issued are sold at a price of $4.00 per share) that we may elect, in our sole discretion, to issue and
sell to Keystone, from time to time from and after the commencement date under the ELOC Purchase Agreement, and subject to applicable
stock exchange rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The actual number of shares
of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to the Selling Stockholder
under the ELOC Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration
statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with the U.S. Securities and Exchange Commission
(SEC), See &ldquo;<I>The Keystone Equity Financing</I>&rdquo; for a description of the ELOC Purchase Agreement and &ldquo;<I>Selling Stockholder</I>&rdquo;
for additional information regarding Keystone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are registering the shares
on behalf of the Selling Stockholder, to be offered and sold by it from time to time. We are not selling any securities under this prospectus,
and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus. However, the
actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at
which the shares of our Common Stock are sold. The purchase price per share that Keystone will pay for shares of Common Stock purchased
from us under the ELOC Purchase Agreement will fluctuate based on the market price of our shares at the time we elect to sell shares to
Keystone and, further, to the extent that the Company sells shares of Common Stock under the ELOC Purchase Agreement, substantial amounts
of shares could be issued and resold, which would cause dilution and may impact the Company&rsquo;s stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is listed
on The Nasdaq Capital Market under the symbol &ldquo;ONCO.&rdquo; The last reported sale price of our Common Stock on The Nasdaq Capital
Market on October 30, 2024 was $2.96 per share. We recommend that you obtain current market quotations for our Common Stock prior to
making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder may
offer all or part of the shares for resale from time to time through public or private transactions, at either prevailing market prices
or at privately negotiated prices. Our registration of the shares of Common Stock covered by this prospectus does not mean that the Selling
Stockholder will offer or sell any of the shares. With regard only to the shares the Selling Stockholder sells for its own behalf, the
Selling Stockholder may be deemed an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;). The Company has paid all of the registration expenses incurred in connection with the registration of the shares. We will
not pay any of the selling commissions, brokerage fees and related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will pay the expenses
incurred in registering the shares, including legal and accounting fees. See &ldquo;<I>Plan of Distribution</I>&rdquo; on page 28 of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Investing in our Common
Stock involves certain risks. See &ldquo;<I>Risk Factors</I>&rdquo; on page 8 of this prospectus, included in any accompanying prospectus
supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider
before deciding to purchase these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments
or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">PIPE FINANCING</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">ELOC FINANCING</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of
a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) for the delayed
or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix,
Inc. and our Common Stock. The Selling Stockholder may use this registration statement to sell up to an aggregate of up to 6,250,000 shares
of our Common Stock from time to time through any means described in the section entitled &ldquo;<I>Plan of Distribution</I>.&rdquo; Our
registration of the securities covered by this prospectus does not mean that either we or the Selling Stockholder will issue, offer or
sell, as applicable, any of the securities registered hereunder. Under this registration statement, the Selling Stockholder may, from
time to time, sell the securities offered by it described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. However, we will pay the expenses, other than underwriting
discounts and commissions, associated with the sale of shares pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We and the Selling Stockholder,
as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained
in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read
both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions
&ldquo;<I>Where You Can Find More Information</I>&rdquo; and &ldquo;<I>Incorporation of Certain Information by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No offer of these securities
will be made in any jurisdiction where the offer is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should rely only on the
information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free
writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus
and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other
than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of
an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information
appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus
is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed
materially since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless the context otherwise
indicates, references in this prospectus to &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer, collectively, to Onconetix,
Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated,
all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to the one-for-forty (1:40) reverse
stock split (the &ldquo;Reverse Stock Split&rdquo;) of all of the outstanding shares of the Company&rsquo;s issued and outstanding Common
Stock on September 24, 2024. As the financial statements incorporated by reference in this prospectus were filed prior to the Reverse
Stock Split, the outstanding shares disclosed in such financial statements are presented on a pre-split basis. Future financial statements
filed by the Company retrospectively present the shares on a post-split basis.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_002"></A><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus contains
&ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws, and that involve significant risks and uncertainties.
Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications
of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements
are made or management&rsquo;s good faith belief as of that time with respect to future events and are subject to significant risks and
uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions in other documents we file from
time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Important factors that could
cause such differences include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our projected financial position
and estimated cash burn rate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our estimates regarding expenses,
future revenues and capital requirements;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to continue as
a going concern;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our need to raise substantial
additional capital to fund our operations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our
ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with
Proteomedix AG (&ldquo;Proteomedix&rdquo;); </FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our reliance on third parties,
including Labcorp, to develop, market, distribute and sell our products;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the successful development
of our commercialization capabilities, including sales and marketing capabilities.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain
the necessary regulatory approvals to market and commercialize our products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of market research
conducted by us or others;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain
intellectual property protection for our current products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to protect our
intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual
property rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the possibility that a third
party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights
and that we may incur substantial costs and be required to devote substantial time defending against claims against us;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our reliance on third parties,
including manufacturers and logistics companies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the success of competing therapies
or diagnostics and products that are or become available;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to successfully
compete against current and future competitors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to expand our organization
to accommodate potential growth and our ability to attract, motivate and retain key personnel;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the potential for us to incur
substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause
us to limit our commercialization of our products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">market acceptance of our products,
the size and growth of the potential markets for our current products, and our ability to serve those markets; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disruptions in the business
of the Company or Proteomedix, which could have an adverse effect on their respective businesses and financial results.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;<I>Risk Factors</I>.&rdquo; Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected
in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read this prospectus
and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which
this prospectus forms a part with the understanding that our actual future results, levels of activity, performance and events and circumstances
may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>The SEC allows us to &ldquo;incorporate
by reference&rdquo; certain information that we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we
file later with the SEC will update automatically, supplement and/or supersede the information disclosed in this prospectus. Any statement
contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is
deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the following summary
together with the more detailed information regarding our company, our Common Stock and our financial statements and notes to those statements
included in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial stage
biotechnology company focused on the research, development, and commercialization of innovative solutions for men&rsquo;s health and oncology.
Through our recent acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed
by Proteomedix and approved for sale in the European Union (&ldquo;EU&rdquo;) under the In Vitro Diagnostic Regulation (&ldquo;IVDR&rdquo;),
which we anticipate will be marketed in the U.S. as a lab developed test (&ldquo;LDT&rdquo;) through our license agreement with Labcorp.
We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia
(&ldquo;BPH&rdquo;), a disorder of the prostate. ENTADFI has not generated any revenue from product sales, and Proclarix has generated
only minimal amounts of development revenue since its acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proclarix is an easy-to-use
next generation protein-based blood test that can be done with the same sample as a patient&rsquo;s regular Prostate-Specific Antigen
(&ldquo;PSA&rdquo;) test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA molecules
in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons
including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing for many patients
and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis
and overtreatment that impacts the physician&rsquo;s routine, our healthcare system, and the quality of patients&rsquo; lives. Approximately
10% of all men have elevated PSA levels, commonly referred to as the diagnostic &ldquo;grey zone&rdquo;, of which only 20 - 40% present
clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult to decide if a biopsy is necessary
to verify a potential clinically significant cancer diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proclarix helps doctors and
patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic
support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories
can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked immunosorbent assay
(&ldquo;ELISA&rdquo;) standard, which most diagnostic laboratories are already equipped to process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception in October
2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development,
undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel,
acquiring and developing the technology of our vaccine candidates, organizing and staffing our company, performing business planning,
establishing our intellectual property portfolio and raising capital to support and expand such activities. Following our April 2023 acquisition
of ENTADFI, we shifted our business strategy towards the field of men&rsquo;s health and oncology and deprioritized our preclinical vaccine
programs. Since that time, we have sought to build assets in therapeutics, diagnostics, and clinician services for men&rsquo;s health
and oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In light of (i) the time
and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company&rsquo;s cash runway and indebtedness, the
Company determined to pause its commercialization of ENTADFI during the first quarter of 2024, as it explores strategic alternatives to
monetize ENTADFI, such as a potential sale of the ENTADFI assets. To that end, the Company engaged an investment advisor to assist with
a potential sale or other transaction of the ENTADFI assets during the second quarter of 2024. There is currently no plan to resume commercialization
of ENTADFI, and as such, if we are not able to consummate a sale or other transaction of the ENTADFI assets, we may abandon the assets
and destroy our inventory of the product. In addition, as part of cost reduction efforts and in connection with our initial pause in commercializing
ENTADFI, we terminated three employees involved with the ENTADFI program, effective April 30, 2024, with such individuals to continue
assisting the Company on an as-needed, consulting basis. Based on the current circumstances surrounding ENTADFI, at June 30, 2024, the
ENTADFI assets were fully impaired.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently focusing
our efforts on commercializing Proclarix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proclarix was first CE marked
under the IVD Directive in Europe in January 31, 2019. On October 7, 2022, Proclarix gained CE marking under the IVDR and was registered
in the United Kingdom and Switzerland under applicable regulations. Given Proclarix is CE-marked for sale in the European Union, we expect
to generate revenue from sales of Proclarix by 2025. Although we anticipate these sales to offset some expenses relating to commercial
scale up and development, we expect our expenses will increase substantially in connection with our ongoing activities, as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">commercialize Proclarix;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">hire additional personnel;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">operate as a public company;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtain, maintain, expand and
protect our intellectual property portfolio.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely and will continue
to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and we will continue to rely
on third parties, of which the main suppliers are single-source suppliers, for commercial products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have any products
approved for sale, aside from Proclarix in the EU, from which we have generated only minimal amounts of development revenue since its
acquisition, and ENTADFI, from which we have not generated any revenue from product sales, and for which we have now abandoned commercialization
activities. To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the
initial public offering (&ldquo;IPO&rdquo;), private placements, the proceeds received from warrant exercises and an issuance of debt
in January 2024. We will continue to require significant additional capital to commercialize Proclarix, and to fund operations for the
foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs
through public or private equity or debt financings, third-party (including government) funding and to rely on third-party resources for
marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination
of these approaches, to support our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred net losses
since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from
quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing
activities, our expenditures on other research and development activities and commercialization activities. As of June 30, 2024, the Company
had a working capital deficit of approximately $18.6 million and an accumulated deficit of approximately $82.2 million. We will need to
raise additional capital within the next 12 months to sustain operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until we generate revenue
sufficient to support self-sustaining cash flows, if ever, we will need to raise additional capital to fund our continued operations,
including our product development and commercialization activities related to our current and future products. There can be no assurance
that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide
self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The consolidated
financial statements of Onconetix, which are incorporated by reference in this prospectus, do not include any adjustment that might be
necessary if the Company is unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because of the numerous risks
and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will
be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix, we may not become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and may be forced to reduce our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PIPE Financing and ELOC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">On
October 2, 2024, the Company entered into, and sold to six institutional investor(s) (collectively, the &ldquo;PIPE Investors&rdquo;),
pursuant to a securities purchase agreement (the &ldquo;Securities ELOC Purchase Agreement&rdquo;) an aggregate of 3,499 shares of Series
C convertible preferred stock, par value $0.00001 per share (&ldquo;Series C Preferred Stock&rdquo;), which includes an issuance of 830
shares of Series C Preferred Stock to the lead investor as consideration for the PIPE Investors&rsquo; irrevocable commitment to purchase
shares of the Series C Preferred Stock, and warrants to purchase 591,856 shares of Common Stock at an initial exercise price of $4.38,
subject to adjustment (the &ldquo;PIPE Warrants&rdquo; and, together with the Series C Preferred Stock, the &ldquo;PIPE Securities&rdquo;),
for aggregate cash proceeds to the Company of $2.0 million. Such investment is referred to as the &ldquo;PIPE Financing.&rdquo; Concurrently
with entering into the Securities ELOC Purchase Agreement, the Company also entered into a registration rights agreement with the PIPE
Investors, pursuant to which it has agreed to provide the PIPE Investors with certain registration rights related to the shares of Common
Stock underlying the PIPE Securities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 2, 2024, the Company
also entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility (the &ldquo;ELOC Purchase Agreement&rdquo;)
with Keystone, whereby the Company may offer and sell, from time to time at its sole discretion, and whereby Keystone has committed to
purchase, up to $25.0 million of the Company&rsquo;s newly issued Common Stock, subject to the limitations described herein. Concurrently
with entering into the ELOC Purchase Agreement, the Company also entered into a registration rights agreement with Keystone, pursuant
to which it agreed to provide Keystone with certain registration rights related to the shares issued under the ELOC Purchase Agreement
(the &ldquo;ELOC Registration Rights Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 23, 2024, the
Company filed an amendment (the &ldquo;Amendment&rdquo;) to the Company&rsquo;s Amended and Restated Certificate of Incorporation to effect
a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40).
The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on September 24, 2024
(the &ldquo;Effective Time&rdquo;). The Company&rsquo;s Common Stock continued to be traded on The Nasdaq Capital Market under the symbol
ONCO and began trading on a split-adjusted basis when the market opened on Tuesday, September 24, 2024, under a new CUSIP number, 68237Q104.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Effective Time, every
40 shares of the Company&rsquo;s issued and outstanding Common Stock were converted automatically into one issued and outstanding share
of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and without any change in the par
value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><BR>
Conversion of Series A Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 24, 2024, the
Company issued an aggregate of 142,749 post-Reverse Stock Split shares of Common Stock to Veru Inc. (&ldquo;Veru&rdquo;), following Veru&rsquo;s
election to convert all of the 3,000 shares of Series A preferred stock (&ldquo;Series A Preferred Stock&rdquo;) of the Company issued
to it on September 29, 2023. The Series A Preferred Stock was originally issued to Veru pursuant to an Amendment to Asset Purchase Agreement,
dated September 29, 2023, between the Company and Veru.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion of Series B Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 24, 2024, the
Company issued an aggregate of 6,741,820 post-Reverse Stock Split shares of Common Stock to certain stockholders of the Company (the &ldquo;PMX
Converted Shares&rdquo;) who were formerly holders of outstanding capital stock or convertible securities (the &ldquo;Sellers&rdquo;)
of Proteomedix AG (&ldquo;Proteomedix&rdquo;), pursuant to the automatic conversion of all the 2,696,729 shares of Series B preferred
stock (&ldquo;Series B Preferred Stock&rdquo;) of the Company, which Series B Preferred Stock was originally issued to the Sellers on
December 15, 2023. The Series B Preferred Stock was originally issued to the Sellers pursuant to a Share Exchange Agreement, dated December
15, 2023, between the Company, Proteomedix and the Sellers (the &ldquo;Share Exchange Agreement&rdquo;), and were subject to automatic
conversion following (i) the Company&rsquo;s receipt of stockholder approval for the issuance of the PMX Converted Shares and (ii) the
effectiveness of the Reverse Stock Split, which provided for a sufficient number of authorized shares to issue the PMX Converted Shares,
as contemplated by the Share Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Altos Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 24, 2024, pursuant
to the Subscription Agreement, dated&nbsp;<FONT STYLE="background-color: white">December 18, 2023, between the Company and Altos Venture
AG (&ldquo;Altos&rdquo; and such agreement, the &ldquo;Subscription Agreement&rdquo;), the Company issued an aggregate of 513,424 units
(the &ldquo;Units&rdquo;) to Altos, each Unit comprised of (i) one share of Common Stock and (ii) one pre-funded warrant (collectively,
the &ldquo;Altos Warrants&rdquo;) to purchase 0.3 shares of Common Stock at an exercise price of $0.04 per share. The Altos Warrants were
immediately exercisable at any time on or after the date of issuance and had a term of exercise of five (5)&nbsp;years from the date of
issuance.&nbsp;Additional shares are issuable to Altos to the extent Altos continues to hold Common Stock included in the Units and if
the VWAP during the 270 days following closing is less than $10.00, as set forth in the Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">On
September 24, 2024, Altos exercised all of the Altos Warrants, and the Company issued to Altos an additional 154,027 shares of Common
Stock upon such exercise.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Veru Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Previously, on April 19, 2023,
the Company entered into an asset purchase agreement with Veru (the &ldquo;Veru APA&rdquo;). Pursuant to the terms of the Veru APA, the
Company agreed to provide Veru with initial consideration totaling $20.0 million, consisting of (i) $6.0 million paid upon the closing
of the transaction, (ii) an additional $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023, and
(iii) an additional $10.0 million in the form of two equal (i.e. each for $5.0 million) non-interest bearing notes payable, each due on
April 19, 2024 (the &ldquo;April Veru Note&rdquo;) and September 30, 2024 (the &ldquo;September Veru Note&rdquo;). On September 29, 2023,
the Company entered into an amendment (the &ldquo;Veru Amendment&rdquo;) of the Veru APA. Pursuant to the Veru Amendment, the $4.0 million
note payable originally due on September 30, 2023, was deemed paid and fully satisfied upon (1) the payment to Veru of $1 million in immediately
available funds on September 29, 2023, and (2) the issuance to Veru by October 3, 2023, of 3,000 shares of Series A Preferred Stock of
the Company. Previously, on April 24, 2024, the Company entered into a Forbearance Agreement with Veru (the &ldquo;Original Forbearance
Agreement&rdquo;). Pursuant to the Original Forbearance Agreement, Veru agreed, among other things, to forbear from exercising its rights
and remedies under the April Veru Note until March 31, 2025 (the &ldquo;April 2024 Forbearance Period&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;On September 19, 2024,
the Company entered into an Amended and Restated Forbearance Agreement with Veru (the &ldquo;A&amp;R Forbearance Agreement&rdquo;) which
amends and restates the Original Forbearance Agreement in its entirety. Pursuant to the A&amp;R Forbearance Agreement, Veru will forbear
from exercising its rights under both the April Veru Note and the September Veru Note, subject to the terms and conditions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Pursuant
to the A&amp;R Forbearance Agreement, the April 2024 Forbearance Period continues to end on the earlier of (a)&nbsp;March&nbsp;31, 2025
and (b)&nbsp;the occurrence of an Event of Default (as defined in the A&amp;R Forbearance Agreement). The A&amp;R Forbearance Agreement
also extends the due date for the&nbsp;</FONT>September Veru Note until the earlier to occur of: (i) June&nbsp;30, 2025 or (ii) the occurrence
of any Event of Default.&nbsp;<FONT STYLE="background-color: white">The A&amp;R Forbearance Agreement also effected certain modifications
to the payment terms in the Original Forbearance Agreement and amended certain terms of the September Veru Note as summarized below.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Pursuant
to the A&amp;R Forbearance Agreement, the Company agreed to make the following required payments (the &ldquo;Required Payments&rdquo;)
during the April 2024 Forbearance Period first to accrued and unpaid interest under the April Veru Note and then any remainder to the
outstanding principal amount of the April Veru Note:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interest at the rate of 10%
per annum shall accrue on any unpaid principal balance of the April Veru commencing on April 20, 2024 through the date that the outstanding
principal balance under the April Veru Note is paid in full;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">monthly payments equal to 25%
(increased from 15% in the Original Forbearance Agreement) of (i) the monthly cash receipts of Proteomedix for the licensing or sale
of any products or services, (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix anywhere
in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries for milestone payments or royalties from Labcorp
cash receipts of the Company or its subsidiaries from certain sale or licensing revenues or payments (the Ordinary Cash Revenue&rdquo;),
which increased amount shall begin on October 20, 2024 for cash receipts in September 2024;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">payment of 20% (increased from
10% in the Original Forbearance Agreement) of the net proceeds from certain financing or other transactions outside the ordinary course
of business completed by the Company or any of its subsidiaries during the April 2024 Forbearance Period, which increased amount will
begin for any net proceeds received after September 19, 2024;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">15% of the Ordinary Cash Revenue
generated in August 2024 shall be due to Veru on September 26, 2024 (the &ldquo;September Veru Payment&rdquo;); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The remaining balance of the
April Veru Note will be due at the end of the April 2024 Forbearance Period.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Company and Veru also agreed to the following amendments to the September Veru Note in the A&amp;R Forbearance Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As noted above, an extension of the maturity date to June 30, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September Veru Note commencing on October 1, 2024 through the date that the outstanding principal balance under the September Veru Note is paid in full;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any amounts owed on the September Veru Note, including but not limited to unpaid principal and accrued interest, will be paid in cash or, upon the mutual written consent of Veru and the Company, in shares of the Company&rsquo;s Common Stock or a combination of cash and the Company&rsquo;s Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Following full repayment of all principal and interest under the April Veru Note, the Company will make the Required Payments first towards accrued and unpaid interest under the September Veru Note and then towards the remaining principal balance payable under the September Veru Note;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If the aggregate unpaid principal outstanding under the April Veru Note and the September Veru Note and all accrued and unpaid interest thereon is repaid in cash on or before December 31, 2024, then the total principal balance under the September Veru Note that will be payable by the Company in satisfaction of its obligations under the September Veru Note will be reduced from $5,000,000 to $3,500,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">On September 26, 2024, Veru and the Company entered
into a waiver agreement, pursuant to which Veru postponed the Company&rsquo;s obligation to make the September Veru Payment until the
earlier of (i) the date upon which the Company consummates a financing transaction in which it raises gross proceeds of greater or equal
to $1,000,000 and (ii) October 4, 2024. The Company paid the September Veru Payment on October 10, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrant Inducement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 11, 2024, the Company,
entered into common stock preferred investment options exercise inducement offer letters (the &ldquo;Inducement Letter&rdquo;) with certain
holders of existing preferred investment options to purchase shares of the Company&rsquo;s common stock at the original exercise prices
of $101.84 and $43.60 per share, issued on August 11, 2022 and August 2, 2023, respectively, pursuant to which the holders agreed to exercise
for cash such existing preferred investment options to purchase an aggregate of 186,465 of the Company&rsquo;s common stock, at a reduced
exercise price of $6.00 per share, in consideration for the Company&rsquo;s agreement to issue new preferred investment options (the &ldquo;PIOs&rdquo;)
to purchase up to an aggregate of 559,397 shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transaction closed on
July 12, 2024 and the Company received aggregate net proceeds of approximately $0.9 million from the exercise of the existing preferred
investment options by the holders and the sale of the Inducement PIOs, after deducting placement agent fees and other offering expenses
payable by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company engaged H.C.
Wainwright &amp; Co., LLC (&ldquo;Wainwright&rdquo;) to act as its exclusive placement agent in connection with the Warrant Inducement
and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the existing preferred investment options
as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the existing preferred investment options, plus the
reimbursement of up to $85,000 in certain expenses. The Company also agreed to (i) issue to Wainwright or its designees an aggregate of
13,054 preferred investment options, and (ii) upon any exercise for cash of the Inducement PIOs, 7.5% of the aggregate exercise price
and such number of warrant to purchase shares of common stock equal to 7.0% of the aggregate number of such shares of common stock underlying
the Inducement PIOs that have been exercised, which warrants will have substantially the same terms as the Placement Agent Inducement
PIOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Inducement PIOs have
an initial exercise price of $6.00 per share, subject to adjustment; one-third of such preferred investment options will expire five years
from the date of stockholder approval (September 5, 2024), and the remaining two-thirds will expire twenty-four months from such date.
The Placement Agent Inducement PIOs have an initial exercise price of $7.50 per share, subject to adjustment, and will expire five years
from the issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, per the terms
of the Inducement Letter, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any other
registration statement with the SEC (in each case, subject to certain exceptions) until the later of (i) the filing of a definitive proxy
statement on Schedule 14A for the purpose of obtaining the requisite stockholder approval and (ii) 30 days after the closing date. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letter) until six months
after the closing date (subject to certain exceptions).</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 3pt 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Common Stock outstanding prior to this offering</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 79%"><FONT STYLE="font-size: 10pt">8,294,734 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Shares of Common Stock offered by the Selling Stockholder</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Up to 6,250,000 shares of Common Stock (assuming the shares to be issued are sold at a price of $4.00 per share)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">14,544,734 shares (assuming the issuance of all shares of Common Stock issuable under the ELOC Purchase Agreement)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not selling any securities under this prospectus,
    and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
    up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
    of our Common Stock pursuant to the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone
    may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common
    Stock are sold.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the ELOC Purchase Agreement, 30% of
    the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of the Company&rsquo;s
    Series C Preferred Stock.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Amended and Restated Forbearance
    Agreement, dated September 19, 2024, between the Company and Veru, we are required to pay to Veru 20% of the net proceeds received from
    any sale of Common Stock under the ELOC Purchase Agreement to pay down our obligations to Veru.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Terms of this offering</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Selling Stockholder, including its transferees, donees, pledgees, assignees, and successors-in-interest, may sell, transfer, or otherwise dispose of any or all of the shares of Common Stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. The shares of Common Stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq symbol</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ONCO.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our securities involves significant risks. Before making a decision whether to invest in our securities, please read the information contained in or incorporated by reference under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this prospectus, the documents we have incorporated by reference herein and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus. See &ldquo;<I>Incorporation of Certain Information by Reference</I>&rdquo; and &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus, in our most recent
Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that
we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, before making
an investment decision pursuant to this.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business, financial condition
and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties
not presently known to us or that we currently deem immaterial that may adversely affect us in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to This Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B><I>It is not possible to predict the actual number of shares
of our Common Stock, if any, we will sell under the ELOC Purchase Agreement, or the actual gross proceeds resulting from those sales or
the dilution to you from those sales. Further, we may not have access to the full amount available under the ELOC Purchase Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the ELOC Purchase Agreement, Keystone
shall purchase from us up to the lesser of (i) $25.0 million in shares of our Common Stock and (ii) 1,658,525 shares, representing 19.99%
of the total number of shares of Common Stock outstanding immediately prior to the execution of the ELOC Purchase Agreement (the &ldquo;Exchange
Cap&rdquo;), upon the terms and subject to the conditions and limitations set forth in the ELOC Purchase Agreement (the &ldquo;Keystone
Commitment Amount&rdquo;); provided, however, that such limitations will not apply if we obtain stockholder approval to issue additional
shares of Common Stock. On October 11, 2024 the Company obtained stockholder approval to issue shares to Keystone in excess of the Exchange
Cap. Accordingly, we have reserved 6,250,000 shares for issuance under the ELOC Purchase Agreement and resale pursuant to this prospectus.
The shares of our Common Stock that may be issued under the ELOC Purchase Agreement may be sold by us to Keystone at our discretion from
time to time from the Commencement Date (as defined below) until the earliest to occur of (i) the 36-month anniversary of the effective
date of the registration statement of which this prospectus forms a part, (ii) the date on which Keystone has purchased the Keystone Commitment
Amount pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock fails to be listed or quoted on Nasdaq or any
successor Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date on which, pursuant to or within the meaning of
any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for
the benefit of our creditors.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We generally have the right to control the timing
and amount of any sales of our Common Stock to Keystone under the ELOC Purchase Agreement. Sales of our Common Stock, if any, to Keystone
under the ELOC Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide
to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant to the ELOC Purchase
Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Keystone Commitment Amount or how much in proceeds
we may obtain under the ELOC Purchase Agreement. If we cannot sell securities under the Keystone Equity Financing, we may be required
to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity
and cash position.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the purchase price per share of Common
Stock to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement, if any, will
fluctuate based on the market prices of our Common Stock at the time we make such election, it is not possible for us to predict, as of
the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to Keystone under the
ELOC Purchase Agreement, the purchase price per share that Keystone will pay for shares of Common Stock purchased from us under the ELOC
Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Keystone under the ELOC Purchase Agreement.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering 6,250,000 shares of our Common Stock under this
prospectus. As of October 30, 2024, there were 8,294,734 shares of Common Stock outstanding. If all of the 6,250,000 shares of our Common
Stock offered for resale by the Selling Stockholder under this prospectus were issued and outstanding as of October 30, 2024, such shares
would represent approximately 42.97% of total number of shares of our Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The actual number of shares of our Common Stock
Issuable will vary depending on the then current market price of shares of our Common Stock sold to the Selling Stockholder in this offering
and the number of shares of our Common Stock we ultimately elect to sell to the Selling Stockholder under the ELOC Purchase Agreement.
If it becomes necessary for us to issue and sell to Keystone under the ELOC Purchase Agreement more than the 6,250,000 shares of our Common
Stock (assuming the shares are sold at a price of $4.00 per share) being registered for resale under this prospectus in order to receive
aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must file with the SEC one or more additional registration
statements to register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock we wish to sell
from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any
additional shares of our Common Stock under the ELOC Purchase Agreement. Keystone is not obligated to buy any Common Stock under the ELOC
Purchase Agreement if such shares, when aggregated with all other Common Stock then beneficially owned by Keystone and its affiliates
(as calculated pursuant to Section 13(d) of the Securities Exchange Act, and Rule 13d-3 promulgated thereunder), would result in Keystone
beneficially owning Common Stock in excess of 4.99% of the then-outstanding shares of Common Stock. Our inability to access a portion
or the full amount available under the ELOC Purchase Agreement, in the absence of any other financing sources, could have a material adverse
effect on our business or results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Keystone will pay less than the then-prevailing
market price for our Common Stock, which could cause the price of our Common Stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price of our Common Stock to be sold
to Keystone under the ELOC Purchase Agreement is derived from the market price of our Common Stock on Nasdaq. Shares to be sold to Keystone
pursuant to the ELOC Purchase Agreement will be purchased at a discounted price.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, we may effect sales to Keystone pursuant
to a Fixed Purchase Notice (as defined below) at a purchase price equal to the lesser of 90% of (i) the daily VWAP (as defined below)
of the Common Stock for the five trading days immediately preceding the applicable Fixed Purchase Date (as defined below) and (ii) the
closing price of a share of Common Stock on the applicable Fixed Purchase Date during the full trading day on such applicable Purchase
Date. See &ldquo;<I>Keystone Committed Equity Financing</I>&rdquo; for more information.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this pricing structure, Keystone
may sell the shares they receive immediately after receipt of such shares, which could cause the price of our Common Stock to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors who buy shares of Common Stock
from Keystone at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the ELOC Purchase Agreement, we have
discretion, to vary the timing, price and number of shares of Common Stock we sell to Keystone. If and when we elect to sell shares of
Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone may resell all, some
or none of such shares at any time or from time to time in its sole discretion and at different prices. As a result, investors who purchase
shares from Keystone in this offering at different times will likely pay different prices for those shares, and so may experience different
levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience
a decline in the value of the shares they purchase from Keystone in this offering as a result of future sales made by us to Keystone at
prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares
to Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence
of our arrangements with Keystone may make it more difficult for us to sell equity or equity-related securities in the future at a time
and at a price that we might otherwise wish to effect such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Future resales and/or issuances of shares
of Common Stock, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price of our
shares to drop significantly.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of our Common Stock that may be issued
under the ELOC Purchase Agreement may be sold by us to Keystone at our discretion from time to time from the date of effectiveness of
effectiveness of the registration statement of which this prospectus forms a part until the earliest to occur of (i) the 36-month anniversary
of the effective date of the registration statement of which this prospectus forms a part, (ii) the date on which Keystone has purchased
the Aggregate Limit pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock fails to be listed or quoted on
Nasdaq or any successor Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date on which, pursuant to or within
the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general
assignment for the benefit of our creditors.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price for shares of our Common Stock
that we may sell to Keystone under the ELOC Purchase Agreement will fluctuate based on the trading price of shares of our Common Stock.
Depending on market liquidity at the time, sales of shares of our Common Stock may cause the trading price of shares of our Common Stock
to decrease. We generally have the right to control the timing and amount of any future sales of shares of our Common Stock to Keystone.
Additional sales of shares of our Common Stock, if any, to Keystone will depend upon market conditions and other factors to be determined
by us. We may ultimately decide to sell to Keystone all, some or none of the additional shares of our Common Stock that may be available
for us to sell pursuant to the ELOC Purchase Agreement. If and when we do sell shares of our Common Stock to Keystone, after Keystone
has acquired shares of our Common Stock, Keystone may resell all, some or none of such shares of our Common Stock at any time or from
time to time in its discretion and at different prices. Therefore, sales to Keystone by us could result in substantial dilution to the
interests of other holders of shares of our Common Stock. In addition, if we sell a substantial number of shares of our Common Stock to
Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the shares held by Keystone will represent a significant
portion of our public float and may result in substantial decreases to the price of our Common Stock. The actual sales of shares of our
Common Stock or the mere existence of our arrangement with Keystone may also make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect such sales.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of shares of our Common Stock
could drop significantly if Keystone sells shares of Common Stock or is perceived by the market as intending to sell them. These factors
could also make it more difficult for us to raise additional funds through future offerings of shares of our Common Stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may use proceeds from sales of our Common
Stock made pursuant to the ELOC Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will have broad discretion over the use of
proceeds from sales of our Common Stock made pursuant to the ELOC Purchase Agreement, including for any of the purposes described in the
section entitled &ldquo;<I>Use of Proceeds</I>,&rdquo; and you will not have the opportunity, as part of your investment decision, to
assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use
of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds
from this offering as set forth in &ldquo;<I>Use of Proceeds</I>,&rdquo; we are not obligated to do so. The failure by us to apply these
funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating
results or enhance the value of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>There is substantial
doubt about our ability to continue as a &ldquo;going concern,&rdquo; and we will require substantial additional funding to finance our
long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate some
or all of our products and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future. As of June 30, 2024, the Company had cash of
approximately $0.9&nbsp;million, a working capital deficit of approximately $18.6&nbsp;million and an accumulated deficit of approximately
$82.2 million. In addition, as of October 30, 2024, the Company&rsquo;s cash balance was approximately $595,000, and the Company has $5.0
million of debt, plus interest, due in each of March 2025 and June 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We estimate, as of the
date of this prospectus, that our current cash balance is only sufficient to fund our operations into November 2024. We believe that
we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations and
liabilities, and otherwise support the Company&rsquo;s working capital needs and business activities, including making the remaining
payments to Veru and the development and commercialization of Proclarix. Management&rsquo;s plans include generating product revenue
from sales of Proclarix, which is still subject to further successful commercialization activities within certain jurisdictions. In
addition, the Company has now abandoned commercialization activities for ENTADFI and it is exploring strategic alternatives for its
monetization, such as a potential sale of the ENTADFI assets. If we are not able to consummate a sale or other transaction of the
ENTADFI assets, we may abandon the assets and destroy our inventory of the product. Management&rsquo;s plans also include attempting
to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in
place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if
at all. If the Company is unable to secure additional capital, it may be required to delay or curtail any future commercialization
of products, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain
operations and meet its obligations, or, if it is required to, file for bankruptcy. These conditions raise substantial doubt about
the Company&rsquo;s ability to continue as a going concern for a period of time within one year from the issuance of the condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our future capital requirements
will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for Proclarix and other products for which we have received or will receive marketing approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any product liability or other lawsuits related to our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the expenses needed to attract, hire, and retain skilled personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the revenue, if any, received from commercial sales of Proclarix or other products for which we may receive marketing approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing our patents or other intellectual property rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the costs of operating as a public company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to raise additional
funds will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional
funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce or terminate our business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our current liabilities
are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors, were to demand payment,
we would be unable to pay.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2024, we had total current liabilities of approximately
$20.6 million, including accounts payable of approximately $3.2 million, accrued expenses of approximately $1.4 million, and related party
subscription liability of $0.9 million. As of October 30, 2024, the Company&rsquo;s cash balance was approximately $595,000, and the Company
has $5.0 million of debt, plus interest, due in each of March 2025 and June 2025. We are currently considering strategic options for ENTADFI,
including a potential sale or abandonment, and plan to seek funding to support our operations. However, the level of our current liabilities
may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom these payments are due
were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments, we would be subject to
liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency. Under such a scenario,
our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on third parties, including
Labcorp, to develop, market, distribute and sell our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to receive revenues
is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors. In particular, the development
and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive license agreement that grants
Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&rsquo;s
intellectual property covered by the license, in the United States for identification, screening, staging, predisposition, diagnosis,
prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not have control over Labcorp&rsquo;s
development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue to advance development and commercialization
efforts, or that Labcorp will successfully commercialize Proclarix in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Labcorp may terminate or
seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial condition. If Labcorp
terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product development and
commercialization efforts, potentially leading to a loss of revenue and market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if Labcorp
is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization partner,
or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business,
financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>PIPE FINANCING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">On
October 2, 2024, the Company entered into, and sold to the PIPE Investors, pursuant to the Securities Purchase Agreement an aggregate
of 3,499 shares of Series C Preferred Stock, which includes an issuance of 830 shares of Series C Preferred Stock to the lead investor
as consideration for the PIPE Investors&rsquo; irrevocable commitment to purchase shares of the Series C Preferred Stock, and 591,856
PIPE Warrants, for aggregate cash proceeds to the Company of $2.0 million. Concurrently with entering into the Securities Purchase Agreement,
the Company also entered into a registration rights agreement with the PIPE Investors, pursuant to which it has agreed to provide the
PIPE Investors with certain registration rights related to the shares of Common Stock underlying the PIPE Securities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">The
material terms of the Series C Preferred Stock and the PIPE Warrants are set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Series
C Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><I>Certificate of Designations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>General<B>.&nbsp;</B></I>Pursuant
to the Certificate of Designations, the Company has authorized the issuance of up to 10,000 shares of Series C Preferred Stock, each having
a stated value of $1,000 per share (the &ldquo;Stated Value&rdquo;). The Company has issued 3,499&nbsp;shares of the Company Series C
Preferred Stock to the PIPE Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Ranking</I>.&nbsp;&nbsp;Except
(i) for the Series A Preferred Stock of the Company (of which there are no shares currently outstanding), which shall be Parity Stock,
and (ii) to the extent that the Required Holders (as defined in the Securities Purchase Agreement) expressly consent to the creation of
Parity Stock or Senior Preferred Stock, all shares of capital stock of the Company will be junior in rank to all Preferred Shares with
respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Dividends</I>.&nbsp;The
holders of Series C Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends
actually paid on shares of Common Stock, when and if actually paid. In addition, from and after the occurrence and during the continuance
of any Triggering Event, dividends (&ldquo;Default Dividends&rdquo;) will accrue on the Stated Value of each Preferred Share at a rate
of fifteen percent (15.0%) (the &ldquo;Default Rate&rdquo;) per annum. Default Dividends are payable by way of inclusion of Default Dividends
in the Conversion Amount (as defined below) on each Conversion Date, upon any redemption or upon any required payment upon any Bankruptcy
Triggering Event. In the event that such Triggering Event is subsequently cured (and no other Triggering Event then exists), the accrual
of Default Dividends will cease to be effective as of the calendar day immediately following the date of such cure; provided that Default
Dividends as calculated and unpaid during the continuance of such Triggering Event will continue to apply to the extent relating to the
days after the occurrence of such Triggering Event through and including the date of such cure of such Triggering Event.<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion Rights</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Conversion
at Option of </I>Holder.&nbsp;&nbsp;Each holder is entitled to convert any portion of the outstanding Preferred Shares held by such holder
into validly issued, fully paid and non-assessable Conversion Shares at the Conversion Rate. Except as otherwise provided in the Certificate
of Designations, the number of Conversion Shares issuable upon conversion of any Preferred Share will be determined by dividing (x) the
Conversion Amount of such Preferred Share by (y) the Conversion Price (the &ldquo;Conversion Rate&rdquo;). As used herein, the term &ldquo;Conversion
Amount&rdquo; means, with respect to each Preferred Share, as of the applicable date of determination, the sum of (1) the Stated Value
thereof&nbsp;<U>plus</U>&nbsp;(2) any Default Dividends thereon as of such date of determination&nbsp;<U>plus</U>&nbsp;(3) any other amounts
owed to such PIPE Investor pursuant to the terms of the Certificate of Designations or any other Transaction Document; and the term &ldquo;Conversion
Price&rdquo; means, with respect to each Preferred Share, as of any Conversion Date or other date of determination, $4.5056, subject to
adjustment as provided in the Certificate of Designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Conversion
at the Option of the Holder Upon the Occurrence of a Triggering Event</I>. After the Stockholder Approval Date (as defined in the Securities
Purchase Agreement), if a Triggering Event occurs and is continuing, at any time after the earlier of a holder&rsquo;s receipt of a Triggering
Event Notice and such holder becoming aware of such Triggering Event (such earlier date, the &ldquo;Alternate Conversion Right Commencement
Date&rdquo;) and ending on the twentieth (20<SUP>th</SUP>) Trading Day after the later of (x) the date such Triggering Event is cured
and (y) such holder&rsquo;s receipt of a Triggering Event Notice (such ending date, the &ldquo;Alternate Conversion Right Expiration Date&rdquo;,
and each such period, an &ldquo;Alternate Conversion Right Period&rdquo;), such holder may, at such holder&rsquo;s option, by delivery
of a Conversion Notice to the Company (the date of any such Conversion Notice, each an &ldquo;Alternate Conversion Date&rdquo;), convert
all, or any number of Preferred Shares held by such holder into shares of Common Stock at the Alternate Conversion Price (each, an &ldquo;Alternate
Conversion&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&ldquo;Alternate
Conversion Price&rdquo; means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable Conversion
Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price
and (y) 80% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including the Trading
Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the &ldquo;Alternate Conversion
Measuring Period&rdquo;). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion
Measuring Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&ldquo;Alternate
Conversion Floor Amount&rdquo; means an amount equal to the product obtained by multiplying (A) the higher of (i) the highest price that
the Common Stock trades at on the Trading Day immediately preceding the relevant Alternate Conversion Date and (ii) the applicable Alternate
Conversion Price and (B) the difference obtained by subtracting (i) the number of shares of Common Stock delivered (or to be delivered)
to such holder on the applicable Share Delivery Deadline with respect to such Alternate Conversion from (ii) the quotient obtained by
dividing (x) the applicable Conversion Amount that such holder has elected to be the subject of the applicable Alternate Conversion, by
(y) the applicable Alternate Conversion Price, without giving effect to the Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&ldquo;Floor
Price&rdquo; means $1.00 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), or,
subject to the rules and regulations of the Principal Market, such lower price as the Company and the Required Holders may agree, from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&ldquo;Triggering
Event Notice&rdquo; means written notice from the Company delivered to each holder within two Business Days after the occurrence of a
Triggering Event) that includes (i) a reasonable description of the applicable Triggering Event, (ii) a certification as to whether, in
the reasonable opinion of the Company, such Triggering Event is capable of being cured and, if applicable, a reasonable description of
any existing plans of the Company to cure such Triggering Event and (iii) a certification as to the date the Triggering Event occurred
and, if cured on or prior to the date of such Triggering Event Notice, the applicable Alternate Conversion Right Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&ldquo;Triggering
Event&rdquo; includes, but is not limited to, the following, subject to certain cure periods as set forth in the Certificate of Designations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(i) the failure
to file a registration statement for the resale of the shares of Common Stock underlying the Preferred Shares and the PIPE Warrants, or
the failure of the applicable Registration Statement to be declared effective by the SEC, ten (10) days after the applicable deadline;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ii) the failure
to maintain the effectiveness of a registration statement pursuant to the terms of the Registration Rights Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iii) the suspension
from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5)
consecutive Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iv) failure to
cure a Conversion Failure or a Delivery Failure (as defined in the PIPE Warrants) by delivery of the required number of shares of Common
Stock within the requisite time frame;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(v) failure to
maintain authorized, but unissued shares equal to 150% of the shares underlying the Preferred Shares and the PIPE Warrants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vi) the occurrence
of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $500,000 of Indebtedness of the Company
or any of its Subsidiaries, or a final judgment or judgments for the payment of money aggregating in excess of $500,000 are rendered against
the Company and/or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vii) the institution,
commencement, court order or decree by or against the Company or any Subsidiary of certain bankruptcy, insolvency, reorganization or liquidation
proceedings or other proceedings for the relief of debtors (the &ldquo;Bankruptcy Triggering Events&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(viii) the Company
and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any
payment with respect to any Indebtedness in excess of $500,000 due to any third party (other than, with respect to unsecured Indebtedness
only, payments contested by the Company and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect
to which adequate reserves have been set aside for the payment thereof in accordance with Generally Accepted Accounting Principles (GAAP))
or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $500,000, which breach or violation
permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other
circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default
under any agreement binding the Company or any Subsidiary, which default or event of default would or is likely to have a material adverse
effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition)
or prospects of the Company or any of its Subsidiaries, individually or in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ix) the Company
or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to
Material Adverse Effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction
Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(x) a false or
inaccurate certification (including a false or inaccurate deemed certification) by the Company that either (A) the Equity Conditions are
satisfied, (B) there has been no Equity Conditions Failure, or (C) as to whether any Triggering Event has occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xi) any breach
or failure in any respect by the Company or any Subsidiary to comply with any provision of the covenants included in the Certificate of
Designations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xii) any Preferred
Shares remain outstanding on or after April 2, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiii) any Change
of Control occurs without the prior written consent of the Required Holders, which consent will not be unreasonably withheld, conditioned
or delayed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiv) any Material
Adverse Effect occurs; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xv) any provision
of any Transaction Document will at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding
on or enforceable against the Company, or the validity or enforceability thereof is contested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion Price Adjustments</I>.
If on the ninetieth (90th) calendar day and one hundred eightieth (180) calendar day (each an &ldquo;Adjustment Date&rdquo;) following
the occurrence of the later of (x) the date that Company stockholders approve the transaction and all securities issuable to the PIPE
Investors in connection therewith, as required by Nasdaq (&ldquo;Stockholder Approval&rdquo;) and (y) the earlier of (a) the effective
date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series C Preferred
Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, as amended (the &ldquo;Securities Act&rdquo;),
the Conversion Price then in effect is greater than the Market Price then in effect (the &ldquo;Adjustment Price&rdquo;), the Conversion
Price will automatically lower to the Adjustment Price. As used herein, &ldquo;Market Price&rdquo; means, with respect to any Adjustment
Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on the Principal Market on any Trading Day
during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to such applicable Adjustment
Date (each, a &ldquo;Market Price Measuring Period&rdquo;). All such determinations to be appropriately adjusted for any stock dividend,
stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during
such applicable Market Price Measuring Period. Only downward adjustments will be made.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Share Combination Event
Adjustment</I>.&nbsp;In addition to the adjustments set forth above, if at any time and from time to time on or after Stockholder Approval,
there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the Common Stock
(each, a &ldquo;Share Combination Event&rdquo;, and such date thereof, the &ldquo;Share Combination Event Date&rdquo;) and the lowest
VWAP during the ten consecutive (10) Trading Day period ending and including the fifth (5) Trading Day immediately preceding the Share
Combination Event Date (the &ldquo;Event Market Price&rdquo;) (provided if the Share Combination Event is effective after close of trading
on the primary Trading Market, then commencing on the next Trading Day which period will be the &ldquo;Share Combination Adjustment Period&rdquo;)
is less than the Conversion Price then in effect, then at the close of trading on the primary Trading Market on the last day of the Share
Combination Adjustment Period, the Conversion Price then in effect on such fifth (5th) Trading Day will be reduced (but in no event increased)
to the Event Market Price, but not less than the Floor Price. Notwithstanding the foregoing, if one or more Share Combination Events occur
prior to Stockholder Approval being obtained and a reduction of the Conversion Price did not occur, once Stockholder Approval is obtained,
the Conversion Price will automatically be reduced to equal the lowest Event Market Price with respect to any Share Combination Event
that occurred prior to Stockholder Approval being obtained, but not less than the Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Adjustments
for Dilutive Issuances or Variable Price Securities</I>. If and whenever the Company grants, issues or sells (or enters into any agreement
to grant, issue or sell), or pursuant to the provisions of the Certificate of Designations is deemed to have done any of the foregoing,
but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold, any shares of Common Stock
for a consideration price per share (the &ldquo;New Issuance Price&rdquo;) less than a price equal to the Conversion Price in effect immediately
prior to such granting, issuance or sale (such Conversion Price then in effect is referred to herein as the &ldquo;Applicable Price&rdquo;)
(the foregoing a &ldquo;Dilutive Issuance&rdquo;), then, immediately after such Dilutive Issuance, the Conversion Price then in effect
will be reduced to an amount equal to the New Issuance Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Additionally,
if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities that are issuable pursuant to
such agreement or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with
the market price of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, (each of the formulations for
such variable price being herein referred to as, the &ldquo;Variable Price&rdquo;), the holder shall have the right, but not the obligation,
in its sole discretion to substitute the Variable Price for the Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Voluntary
Adjustment Right</I>.&nbsp;Subject to the rules and regulations of the Principal Market, the Company has the right, at any time, with
the written consent of the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate
by the Company board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Change
of Control Exchange</I>.&nbsp;Upon a change of control of the Company, each holder may require the Company to exchange the holder&rsquo;s
shares of Series C Preferred Stock for consideration equal to the change of Control Election Price, to be satisfied at the Company&rsquo;s
election in either (x) cash or (y) rights convertible into such securities or other assets to which such holder would have been entitled
with respect to such shares of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate
event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Fundamental
Transactions.&nbsp;</I>The Certificate of Designations prohibits the Company from entering specified fundamental transactions (including,
without limitation, mergers, business combinations and similar transactions) unless the Company (or the Company&rsquo;s successor) assumes
in writing all of the Company&rsquo;s obligations under the of Common Stock, except as provided in the transaction documents in the PIPE
Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Redemption
Rights:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Optional
Redemption by the Company.&nbsp;</I>At any time, the Company has the right to redeem in cash all, but not less than all, of the Preferred
Shares then outstanding at a price (the &ldquo;Company Optional Redemption Price&rdquo;) equal to 125% of the greater of (i) the Conversion
Amount being redeemed and (ii) the product of (1) the Conversion Rate with respect to the Conversion Amount being redeemed multiplied
by (2) the greatest closing sale price of the Company&rsquo;s Common Stock on any Trading Day during the period commencing on the date
immediately preceding the date the Company notifies the holders of its election to redeem and the date the Company makes the entire payment
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Mandatory Redemption by
the Company Upon a Bankruptcy Triggering Event.&nbsp;</I>Upon the occurrence and continuation of a Bankruptcy Triggering Event, the Company
will immediately redeem, in cash, each of the Preferred Shares then outstanding at a redemption price equal to the greater of (i) the
product of (A) the Conversion Amount to be redeemed multiplied by (B) 125% and (ii) the product of (X) the Conversion Rate with respect
to the Conversion Amount in effect immediately following the date of initial public announcement (or public filing of bankruptcy documents,
as applicable) of such Bankruptcy Triggering Event multiplied by (Y) the product of (1) 125% multiplied by (2) the greatest closing sale
price of the Common Stock on any Trading Day during the period commencing on the date immediately preceding such Bankruptcy Triggering
Event and ending on the date the Company pays the entire payment required, provided that a Holder may, in its sole discretion, waive such
right to receive payment upon a Bankruptcy Triggering Event, in whole or in part, and any such waiver will not affect any other rights
of such Holder or any other Holder hereunder, including any other rights in respect of such Bankruptcy Triggering Event or any right to
conversion (or Alternate Conversion), as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Voting
Rights</I>. The holders of the Series C Preferred Stock have no voting power and no right to vote on any matter at any time, either as
a separate series or class or together with any other series or class of share of capital stock, and are not entitled to call a meeting
of such holders for any purpose nor are they entitled to participate in any meeting of the holders of Common Stock, except as provided
in the Certificate of Designations (or as otherwise required by applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Covenants</I>.
The Certificate of Designations contains a variety of obligations on the Company&rsquo;s part not to engage in specified activities, which
are typical for transactions of this type. In particular, the Company will not, and will cause the Company&rsquo;s subsidiaries to not,
redeem, repurchase or declare any dividend or distribution on any of its capital stock (other than as required under the Certificate of
Designations). In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach or
default under the of Certificate of Designations or PIPE Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Ownership
Limitation.&nbsp;</I>In no event may any Preferred Shares be converted (or PIPE Warrants be exercised) and shares of Common Stock be issued
to any holder if after giving effect to the issuance of shares of Common Stock upon such conversion of the Preferred Shares (or exercise
of the PIPE Warrants), the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding shares
of Common Stock, which we refer to herein as the &ldquo;<I>PIPE Blocker</I>&rdquo;). The PIPE Blocker may be raised or lowered to any
other percentage not in excess of 9.99% at the option of the applicable holder of the Preferred Shares (or PIPE Warrants), except that
any raise will only be effective upon 61-days&rsquo; prior notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Exchange
Right.&nbsp;</I>If the Company or any of its Subsidiaries consummates any Subsequent Placement (other than with respect to Excluded Securities
(as defined in the Securities Purchase Agreement)), and a holder elects in writing to the Company to participate in such Subsequent Placement,
each such holder may, at the option of such holder as elected in writing to the Company, exchange all, or any part, of the Preferred Shares
of such holder into the securities in such Subsequent Placement (with the aggregate amount of such securities to be issued in such exchange
equal to such aggregate amount of such securities with a purchase price valued at 120% of the Conversion Amount of the Preferred Shares
delivered by such holder in exchange therefor); provided that any such exchange will be subject to all applicable Nasdaq restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Reservation
Requirements.&nbsp;</I>So long as any Series C Preferred Stock remains outstanding, the Company will at all times reserve at least 150%
of the number of shares of Common Stock as will from time to time be necessary to effect the conversion of all Preferred Shares then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Conditions
Precedent to Closing</I>: As set forth in the Securities Purchase Agreement, the obligations of each party to consummate the PIPE Financing
are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Committed
Equity Line of Credit (&ldquo;ELOC&rdquo;), described below under the caption &ldquo;Common Stock Purchase Agreement&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>PIPE Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Exercise
Price</I>. The exercise price of the PIPE Warrants is $4.38, the Nasdaq Minimum Price (as defined below.) The exercise price is subject
to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares
of Common Stock issuable upon the exercise of the Warrant also will be adjusted so that the aggregate exercise price will be the same
immediately before and immediately after any such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Exercise
Price Adjustments</I>. If on an Adjustment Date, the exercise price then in effect is greater than the Market Price then in effect (the
&ldquo;Warrant Adjustment Price&rdquo;), the exercise price will automatically lower to the Warrant Adjustment Price. As used herein,
&ldquo;Market Price&rdquo; means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest closing price
of the Common Stock on the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including, the Trading
Day ended immediately prior to such applicable Adjustment Date (each, a &ldquo;Market Price Measuring Period&rdquo;). All such determinations
to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately
decreases or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments will be made.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Adjustments
for Dilutive Issuances or Variable Price Securities</I>. If and whenever the Company grants, issues or sells (or enters into any agreement
to grant, issue or sell), or pursuant to the provisions of the Warrant is deemed to have done any of the foregoing, but excluding any
Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold any shares of Common Stock for a consideration
price per share (the &ldquo;Warrant New Issuance Price&rdquo;) less than a price equal to the exercise price in effect immediately prior
to such granting, issuance or sale (the foregoing a &ldquo;Warrant Dilutive Issuance&rdquo;), then, immediately after such Warrant Dilutive
Issuance, the exercise price then in effect will be reduced to an amount equal to the Warrant New Issuance Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Additionally,
if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities at a Variable Price, the warrant
holder shall have the right, but not the obligation, in its sole discretion to exercise the PIPE Warrants at the Variable Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Exercise
Period</I>. The PIPE Warrants are exercisable beginning six months after the issuance date (the &ldquo;Initial Exercisability Date&rdquo;)
and expiring on the third anniversary of the Initial Exercisability Date. The PIPE Warrants require &ldquo;buy-in&rdquo; payments to be
made by us for failure to deliver any shares of Common Stock issuable upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Cashless
Exercise</I>. If at the time of exercise of the PIPE Warrants, there is no effective registration statement registering the shares of
the Company Common Stock underlying the PIPE Warrants, such PIPE Warrants may be exercised on a cashless basis pursuant to their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Purchase
Rights; Participation Rights</I>. If the Company issues options, convertible securities, warrants, shares, or similar securities to holders
of the Company shares of the Company Common Stock, each Warrant holder has the right to acquire the same as if the holder had exercised
its Warrant. The holders of the PIPE Warrants are entitled to receive any dividends paid or distributions made to the holders of the Company&rsquo;s
shares of Common Stock on an &ldquo;as if converted&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>Fundamental
Transactions</I>. The PIPE Warrants prohibit the Company from entering into specified fundamental transactions unless the successor entity
assumes all of the Company obligations under the PIPE Warrants under a written agreement before the transaction is completed. Upon specified
corporate events, a Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or
any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event
had the Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified changes
of control, a Warrant holder will have the right to force the Company to repurchase the holder&rsquo;s Warrant for a purchase price in
cash equal to the Black Scholes value, as calculated under the PIPE Warrants, of the then unexercised portion of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="text-transform: uppercase"><B>ELOC
Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
October 2, 2024, the Company entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility with Keystone,
whereby the Company may offer and sell, from time to time at its sole discretion, and whereby Keystone has committed to purchase, up to
$25.0 million of the Company&rsquo;s newly issued Common Stock, subject to the limitations described below. Concurrently with entering
into the ELOC Purchase Agreement, the Company also entered into a registration rights agreement with Keystone, pursuant to which it agreed
to provide Keystone with certain registration rights related to the shares issued under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company may, from time to time and at its sole discretion, direct Keystone to purchase shares of Common Stock upon the satisfaction of
certain conditions set forth in the Common Stock Purchase Agreement at a purchase price per share based on the market price of Common
Stock at the time of sale as computed under the ELOC Purchase Agreement. There is no upper limit on the price per share that Keystone
could be obligated to pay for Common Stock under the ELOC Purchase Agreement. The Company will control the timing and amount of any sales
of Common Stock to Keystone, and Keystone has no right to require the Company to sell any shares to it under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company does not have a right to commence any sales of Common Stock to the Purchaser under the ELOC Purchase Agreement until the time
when all of the conditions to the Company&rsquo;s right to commence sales of Common Stock to the Purchaser set forth in the ELOC Purchase
Agreement have been satisfied, including that a registration statement covering the resale of such shares is declared effective by the
SEC and the final form of prospectus is filed with the SEC (the &ldquo;Commencement Date&rdquo;). Over the 36-month period from and after
the Commencement Date, the Company will control the timing and amount of any sales of Common Stock to the Purchaser. Actual sales of shares
of Common Stock to the Purchaser under the ELOC Purchase Agreement will depend on a variety of factors to be determined by the Company
from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the
appropriate sources of funding and the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the Purchase Agreement
provides that we may sell up to an aggregate of $25.0 million of our shares of our Common Stock to Keystone, only 6,250,000 shares of
our Common Stock (assuming the shares are sold at a price of $4.00 per share) are being registered for resale under the registration statement
that includes this prospectus. If it becomes necessary for us to issue and sell to Keystone under the Purchase Agreement more shares than
are being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $25.0 million under the Purchase
Agreement, we must first file with the SEC one or more additional registration statements to register under the Securities Act the resale
by Keystone of any such additional shares of our Common Stock we wish to sell from time to time under the Purchase Agreement, which the
SEC must declare effective, in each case, before we may elect to sell any additional shares of our Common Stock to Keystone under the
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
no event will the Company issue to the Purchaser under the ELOC Purchase Agreement more than 1,658,525 shares of Common Stock, representing
19.99% of the total number of shares of Common Stock outstanding immediately prior to the execution of the Common Stock Purchase Agreement,
unless (i) the Company obtains the approval of the issuance of such shares by its stockholders in accordance with the applicable stock
exchange rules or (ii) sales of Common Stock are made at a price equal to or in excess of the lower of (A) the closing price immediately
preceding the delivery of the applicable notice to the Purchaser and (B) the average of the closing prices of the Common Stock for the
five business days immediately preceding the delivery of such notice, such that the sales of such Common Stock to the Purchaser would
not count toward the Exchange Cap because they are &ldquo;at market&rdquo; under applicable stock exchange rules. On October 11, 2024
the Company obtained stockholder approval to issue shares to Keystone in excess of the Exchange Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
all cases, the Company may not issue or sell any shares of Common Stock to Keystone under the Common Stock Purchase Agreement which, when
aggregated with all other shares of Common Stock then beneficially owned by Keystone and its affiliates (as calculated pursuant to Section&nbsp;13(d)&nbsp;of
the Securities Exchange Act of 1934, as amended, and Rule&nbsp;13d-3 promulgated thereunder), would result in Keystone beneficially owning
more than 4.99% of the outstanding shares of Common Stock (the &ldquo;ELOC Blocker&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">At
any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is equal to or
greater than $0.05&nbsp;(the &ldquo;Purchase Date&rdquo;), the Company may direct the Purchaser to purchase a specified number of shares
of Common Stock (a &ldquo;Fixed Purchase&rdquo;) not to exceed 100,000 shares at a purchase price equal to the lesser of 90% of (i) the
daily volume weighted average price (the &ldquo;VWAP&rdquo;) of the Common Stock for the five trading days immediately preceding the applicable
Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a share of Common Stock on the applicable Purchase Date for such
Fixed Purchase during the full trading day on such applicable Purchase Date. In any case, the Purchaser&rsquo;s commitment in any single
Fixed Purchase may not exceed $10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
addition, at any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is
equal to or greater than $0.05 and such business day is also the Purchase Date for a Fixed Purchase of an amount of shares of Common Stock
not less than the applicable Fixed Purchase Maximum Amount (as defined in the Common Stock Purchase Agreement) (the &ldquo;VWAP Purchase
Date&rdquo;), the Company may also direct the Purchaser to purchase, on the immediately following business day, an additional number of
shares of Common Stock in an amount up to the Maximum VWAP Purchase Amount (as defined in the Common Stock Purchase Agreement) (a &ldquo;VWAP
Purchase&rdquo;) at a purchase price equal to the lesser of 90% of (i) the closing sale price of the Common Stock on the applicable VWAP
Purchase Date and (ii) the VWAP during the period on the applicable VWAP Purchase Date beginning at the opening of trading and ending
at the VWAP Purchase Termination Time (as defined in the Purchase Agreement). At any time from and after the Commencement Date, on any
business day that is also the VWAP Purchase Date for a VWAP Purchase, the Company may also direct the Purchaser to purchase, on such same
business day, an additional number of shares of Common Stock in an amount up to the Maximum Additional VWAP Purchase Amount (as defined
in the ELOC Purchase Agreement) (an &ldquo;Additional VWAP Purchase&rdquo;) at a purchase price equal to the lesser of 90% of (i) the
closing sale price of the Common Stock on the applicable Additional VWAP Purchase Date and (ii) the VWAP during the Additional VWAP Purchase
Period (as defined in the Common Stock Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of
its Common Stock to Keystone. Pursuant to the ELOC Purchase Agreement, up to 30% of the proceeds from each Fixed Purchase and VWAP Purchase
Notice must be used to redeem shares of Series C Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
ELOC Purchase Agreement contains customary representations, warranties and agreements of the Company and Keystone, limitations and conditions
regarding sales of Common Stock, indemnification rights and other obligations of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">There
are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the ELOC Purchase
Agreement other than a prohibition (with certain limited exceptions) on entering into a dilutive securities transaction during certain
periods when the Company is selling Common Stock to Keystone under the Purchase Agreement. Keystone has agreed that, during the term of
the Purchase Agreement, it will not engage in or effect, directly or indirectly, any short sales involving the Company&rsquo;s securities
or any hedging transaction that transfers the economic risk of ownership of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Purchase Agreement will automatically terminate on the earliest to occur of (i)&nbsp;the expiration of the ELOC Registration Statement,
(ii)&nbsp;the date on which Keystone will have purchased from the Company under the ELOC Purchase Agreement an aggregate limit of shares
of Common Stock as defined therein, (iii)&nbsp;the date on which the Common Stock will have failed to be listed or quoted on Nasdaq or
another U.S. national securities exchange identified as an &ldquo;eligible market&rdquo; in the ELOC Purchase Agreement, (iv)&nbsp;the
30th trading day after the date on which a voluntary or involuntary bankruptcy proceeding involving the Company has been commenced that
is not discharged or dismissed prior to such trading day, and (v)&nbsp;the date on which a bankruptcy custodian is appointed for all or
substantially all of the Company&rsquo;s property or the Company makes a general assignment for the benefit of creditors. The Company
has the right to terminate the ELOC Purchase Agreement at any time after the Commencement Date (as defined in the ELOC Purchase Agreement),
at no cost or penalty, upon one trading day&rsquo;s prior written notice to Keystone. Keystone has the right to terminate the Purchase
Agreement upon ten trading days&rsquo; prior written notice to the Company if certain specified events occur. The Company and Keystone
may also agree to terminate the ELOC Purchase Agreement by mutual written consent. Neither the Company nor Keystone may assign or transfer
the Company&rsquo;s respective rights and obligations under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Concurrent
with the execution of the ELOC Purchase Agreement, the Company entered into a registration rights agreement with Keystone (the &ldquo;ELOC
Registration Rights Agreement&rdquo;), pursuant to which the Company agreed to file a registration statement covering the issuance and
sale of the maximum number of shares issuable under the ELOC Purchase Agreement as may be permitted under applicable rules. The Company
agreed to use its commercially reasonable efforts to cause the registration statement to be filed within 45 days after the closing of
the ELOC Purchase Agreement and to have such registration statement effective within 120 days of such closing (or 90 days of such closing
if the Company is notified by the Securities and Exchange Commission that such registration statement will not be reviewed or subject
to further review).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effect of Sales of our Common Stock under the ELOC Purchase Agreements
on our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Stock being registered for resale in
this offering may be issued and sold by us to the Selling Stockholder from time to time at our discretion, during the terms described
above. The resale by the Selling Stockholder of a significant quantity of shares registered for resale in this offering at any given time,
or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales
of our Common Stock, if any, to Keystone under the ELOC Purchase Agreement will be determined by us in our sole discretion, subject to
the satisfaction of certain conditions in the ELOC Purchase Agreement, and will depend upon market conditions and other factors. We may
ultimately decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant
to the ELOC Purchase Agreement. If we elect to sell Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has
acquired such shares, Keystone may resell all, some or none of such Common Stock at any time or from time to time in its discretion and
at different prices. As a result, investors who purchase Common Stock from Keystone in this offering at different times will likely pay
different prices for those shares of Common Stock, and so may experience different levels of dilution and in some cases substantial dilution
and different outcomes in their investment results. See &ldquo;<I>Risk Factors</I>&mdash;<I>Risks Related to the Committed Equity Financings</I>&mdash;<I>Investors
who buy shares of Common Stock from Keystone at different times will likely pay different prices</I>.&rdquo;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors may experience a decline in the value
of the Common Stock they purchase from Keystone in this offering as a result of future sales made by us to Keystone at prices lower than
the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares of Common Stock
to Keystone under the Keystone ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales of Common Stock or
the mere existence of our arrangement with Keystone may make it more difficult for us to sell equity or equity-related securities in the
future at a time and at a price that we might otherwise wish to effect such sales.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the purchase price per share to be paid by Keystone for the
Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement, if any, will fluctuate based on the market prices
of our Common Stock at the time we make such election, as of the date of this prospectus, it is not possible for us to predict the number
of shares of Common Stock that we will sell to Keystone under the ELOC Purchase Agreement, the actual purchase price per share to be paid
by Keystone for those shares of Common Stock, or the actual gross proceeds to be raised by us from those sales, if any. As of October
30, 2024, there were 8,294,734 shares of Common Stock outstanding. If all of the 6,250,000 shares of our Common Stock offered for resale
by the Selling Stockholders under this prospectus were issued and outstanding as of October 30, 2024, such shares would represent approximately
42.97% of total number of shares of our Common Stock outstanding. The actual number of shares of our Common Stock issuable will vary depending
on the then current market price of shares of our Common Stock sold to the Selling Stockholder in this offering.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of Common Stock ultimately
offered for sale by the Selling Stockholder for resale under this prospectus is dependent upon the number of shares of Common Stock, if
any, we ultimately sell to Keystone under the ELOC Purchase Agreement. Further, if and when we elect to sell shares of Common Stock to
Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone may resell all, some or none of such
shares of Common Stock at any time or from time to time in its discretion and at different prices.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of our shares of Common Stock to
the Selling Stockholder pursuant to the ELOC Purchase Agreement will not affect the rights or privileges of our existing stockholders,
except that the economic and voting interests of each of our existing stockholders will be diluted. Although the number of shares of Common
Stock that our existing stockholders own will not decrease, the shares of Common Stock owned by our existing stockholders will represent
a smaller percentage of our total outstanding shares of Common Stock after any such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the ELOC Purchase Agreement provides
that we may sell up to an aggregate of $25.0 million of shares of our Common Stock to Keystone, only 6,250,000 shares (assuming the shares
are sold at a price of $4.00 per share) are being registered for resale under the registration statement that includes this prospectus.
If it becomes necessary for us to issue and sell more shares than are being registered for resale under this prospectus in order to receive
aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must first file with the SEC one or more additional
registration statements to register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock
we wish to sell from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each case, before we may
elect to sell any additional shares of our Common Stock to Keystone under the ELOC Purchase Agreement.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the number of shares of Common Stock
to be issued to Keystone under the ELOC Purchase Agreement registered hereunder at varying purchase prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assumed Average<BR>
Purchase Price <BR>
Per Share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Registered<BR>
Shares to be Issued if <BR>
Full Purchase<SUP>(1)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage of<BR>
Outstanding Shares <BR>
After Giving Effect <BR>
to the Issuance to <BR>
Keystone<SUP>(2)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gross Proceeds <BR>
from the Sale of Shares <BR>
to Keystone <BR>
Under the <BR>
Purchase<BR>
Agreement</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 23%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.33</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,445,946</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.25</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.00</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,250,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.00</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.50</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,333,333</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.76</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.09</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notes to table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The purchase prices assume a discount to the market prices of
our shares, in accordance with the ELOC Purchase Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The denominator is based on 8,294,734 shares outstanding as of October
30, 2024, adjusted to include the number of shares set forth in the adjacent column that we would have sold to Keystone, assuming the
average purchase price in the first column. The numerator is based on the number of shares issuable pursuant to future sales under the
ELOC Purchase Agreement (that are the subject of this offering) at the corresponding assumed average purchase price set forth in the first
column.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">The closing sale price of our Common Stock on October 30, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the ELOC Purchase
Agreement, 30% of the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of
the Company&rsquo;s Series C Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Amended and
Restated Forbearance Agreement, dated September 19, 2024, between the Company and Veru, we are required to pay to Veru 20% of the net
proceeds received from any sale of Common Stock under the ELOC Purchase Agreement during the to pay down our obligations to Veru.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any proceeds we receive from
the sale of Common Stock under the ELOC Purchase Agreement, net of our obligations to Keystone and Veru, will be used for general corporate
and working capital or for other purposes that the Board, in its good faith, deems to be in the best interest of the Company. No assurances
can be given that we will receive any proceeds from sale of Common Stock under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DETERMINATION OF OFFERING PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder will
offer Common Stock at the prevailing market prices or a privately negotiated price as it may determine from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The offering price of our
Common Stock to be sold by the Selling Stockholder does not necessarily bear any relationship to our book value, assets, past operating
results, financial condition, or any other established criteria of value. The facts considered in determining the offering price were
our financial condition and prospects, our limited operating history and the general condition of the securities market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, there is no
assurance that our Common Stock will trade at market prices in excess of the offering price as prices for our Common Stock in any public
market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation authorizes the issuance of up to 250,000,000 shares of Common Stock, $0.00001 par value per share, and 10,000,000
shares of preferred stock, $0.00001 par value per share. As of the date of this prospectus, we have 8,294,734 shares of Common Stock outstanding,
and 3,499 shares of Series C Preferred Stock issued and outstanding. Our shares of Common Stock are held of record by approximately 37
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;ONCO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of our Amended
and Restated Certificate of Incorporation, holders of our Common Stock are entitled to one vote for each share held on all matters submitted
to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares
of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times
and in such amounts as our Board from time to time may determine. Our Common Stock is not entitled to pre-emptive rights and is not subject
to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution
to stockholders are distributable ratably among the holders of our Common Stock after payment of liquidation preferences, if any, on any
outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of Common Stock are subject to and
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of our Amended
and Restated Certificate of Incorporation, our Board is authorized, without further action by the stockholders, to establish one or more
class or series, and fix the relative rights and preferences of the company&rsquo;s undesignated capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">For
the material terms of the Series C Preferred Stock and the PIPE Warrants, see &ldquo;<I>PIPE Financing</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Delaware Law and Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some provisions of Delaware
law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws could prohibit or delay mergers or other
takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer
our stockholders the opportunity to sell their stock at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of the increased protection of
our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the
disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Delaware Anti-Takeover Statute</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to Section
203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo;
from engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the date these
persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested
stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder
status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo; includes a merger,
asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision
may have an anti-takeover effect with respect to transactions not approved in advance by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Choice of Forum</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, to the fullest extent permitted by law,
that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and certain
other actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A) as to which the Court of Chancery
in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and
the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination),
(B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C) for which the Court of Chancery
does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed
to have consented to service of process on such stockholder&rsquo;s counsel. Although we believe this provision benefits us by providing
increased consistency in the application of law in the types of lawsuits to which it applies, a court may determine that this provision
is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors
and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable
law, subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce
any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision
will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent
in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce
this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section
22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transfer agent and registrar
for our Common Stock is Continental Stock Transfer &amp; Trust Company. The Transfer Agent&rsquo;s address is 1 State Street, 30<SUP>th</SUP>
Floor, New York, New York 10004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is traded
on The Nasdaq Capital Market under the trading symbol &ldquo;ONCO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Elimination of Monetary Liability for Officers
and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation incorporates certain provisions permitted under the Delaware General Corporation Law (&ldquo;DGCL&rdquo;)
relating to the liability of directors. The provisions eliminate a director&rsquo;s liability for monetary damages for a breach of fiduciary
duty, including gross negligence, except in circumstances involving certain wrongful acts, such as the breach of director&rsquo;s duty
of loyalty or acts or omissions, which involve intentional misconduct or a knowing violation of law. These provisions do not eliminate
a director&rsquo;s duty of care. Moreover, these provisions do not apply to claims against a director for certain violations of law, including
knowing violations of federal securities law. Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify
the directors, officers, employees or other agents to the fullest extent permitted by the DGCL. We believe that these provisions will
assist us in attracting and retaining qualified individual to serve as directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent
permitted by the DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect
monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions
will assist us in attracting or retaining qualified individuals to serve as our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The shares of Common Stock
being offered by the Selling Stockholder are those previously issued to the Selling Stockholder, and those issuable to the Selling Stockholder
under the ELOC Purchase Agreement. We are registering the shares of Common Stock in order to permit the Selling Stockholder to offer the
shares for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below lists the
Selling Stockholder and other information regarding the beneficial ownership of the shares of Common Stock by the Selling Stockholder.
The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The third column lists
the shares of Common Stock being offered by this prospectus by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fourth column assumes
the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of the ELOC
Purchase Agreement, the Company may not issue shares to the Selling Stockholder under the ELOC Purchase Agreement to the extent that such
issuance would cause the Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares
of Common Stock which would exceed 4.99% of our then outstanding Common Stock following such issuance, excluding for purposes of such
determination shares of Common Stock issuable under the ELOC Purchase Agreement which have not been issued. The number of shares in the
second and fourth columns do not reflect this limitation. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder may
sell all, some or none of its shares in this offering. See &ldquo;<I>Plan of Distribution</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Selling Shareholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> Prior to <BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of<BR> shares of<BR> Common<BR> Stock<BR> Beneficially<BR> Owned<BR> Prior to<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maximum <BR> Number of <BR> shares of <BR> Common <BR> Stock <BR> to be Sold <BR> Pursuant to <BR> this Prospectus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> After <BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> After <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9.25pt">Keystone Capital Partners, LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">435,646</TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.99</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">435,646</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.91</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Based on 8,294,734 shares outstanding as of October 30, 2024.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock underlying Series C Preferred
Stock held by this Selling Stockholder, after giving effect to the Maximum Percentage (as defined in the Series C Preferred Stock Certificate
of Designations). Keystone Capital Partners LLC is managed by RANZ Group LLC. Frederic Zaino, the Managing Member of RANZ Group LLC,
may be deemed to have investment discretion and voting power over the shares held by Keystone Capital Partners LLC. RANZ Group LLC and
Mr. Zaino each disclaim any beneficial ownership of these shares. The address of the selling stockholder is 139 Fulton Street, Suite
412, New York, NY 10038.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder of
the securities and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of its securities
covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following
methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer
will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in
accordance with the rules of the applicable exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately negotiated transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">settlement of short sales;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in transactions through broker-dealers
that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through the writing or settlement
of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods
of sale; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted
pursuant to applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Broker-dealers engaged by
the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to
be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) Rule 2121; and in the case of a
principal transaction a markup or markdown in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Keystone Capital Partners, LLC has represented to us that at no time
prior to the date of the ELOC Purchase Agreement has such Selling Stockholder or its agents, representatives or affiliates engaged in
or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of
the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock.
Keystone Capital Partners, LLC has agreed that during the term of the ELOC Purchase Agreement, neither Keystone Capital Partners, LLC
nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder and
any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have advised the Selling
Stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of
a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities
offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated balance
sheet of Onconetix, Inc. and Subsidiary as of December 31, 2023, and the related consolidated statements of operations and comprehensive
loss, convertible redeemable preferred stock and stockholders&rsquo; equity (deficit), and cash flows for the year then ended, have been
audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report, which report includes an explanatory
paragraph about the existence of substantial doubt concerning the Company&rsquo;s ability to continue as a going concern. Such financial
statements have been incorporated herein by reference in this prospectus in reliance on the report of such firm given upon their authority
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements of Onconetix, Inc., formerly known as Blue Water Vaccines Inc., as of and for the year ended December 31, 2022, appearing in
the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023, have been audited by CBIZ CPAs P.C. (formerly Mayer Hoffman
McCann, P.C.), independent registered public accounting firm, as set forth in their report, and have been incorporated herein by reference
in this prospectus in reliance upon such report given on the authority of such firm as experts in accounting and auditing, in giving said
reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
of Proteomedix AG as of December 31, 2022, and 2021 and for each of the two years in the period ended December 31, 2022, which have been
incorporated by reference in this prospectus and the registration statement of which it forms a part, have been so included in reliance
on the report of BDO AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. The report on the financial statements contains an explanatory paragraph regarding Proteomedix AG&rsquo;s ability to continue
as a going concern. Such financial statements and audit report are incorporated by reference to the Company&rsquo;s Current Report on
Form 8-K/A, as filed with the SEC on February 27, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ellenoff Grossman &amp; Schole
LLP, New York, New York, will pass upon the validity of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the informational
requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other
information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website at <I>www.sec.gov</I>.
Copies of certain information filed by us with the SEC are also available on our website at <I>www.onconetix.com</I>. Our website is not
a part of this prospectus and is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of
a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance
with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about
us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed
as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The SEC allows us to incorporate
by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring
you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part
of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated, and
those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you
must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any
document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents
listed below (File No. 000-52994) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial
registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement
until the offering of the securities under the registration statement is terminated or completed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea0201701-10k_onconetix.htm">Form 10-K</A>
for the fiscal year ended December 31, 2023, as filed with the SEC on April 11, 2024</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Quarterly Report on Form
10-Q for the quarter ended March 31, 2024, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024045172/ea0206102-10q_onconetix.htm">May 20, 2024</A>, and for the quarter ended June 30, 2024, as filed with
the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024073545/ea0212631-10q_onconetix.htm">August 29, 2024</A>;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Current Reports on Form 8-K
filed on each of <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591-8k_onconetix.htm">January 12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886-8k_onconetix.htm">January 19, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024007414/ea192391-8k_onconetix.htm">January 29, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470-8k_onconetix.htm">February 12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012876/ea193550-8k_onconetix.htm">February 13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/ea0200807-8ka2_onconetix.htm">February 27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024031167/ea0203476-8k_onconetix.htm">April 8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea0204751-8k_oncone.htm">April 26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024042369/ea0205933-8k_oncone.htm">May 13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/ea0207635-8k_onconetix.htm">June 13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052976/ea0207933-8ka1_onconet.htm">June 14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024060635/ea0209277-8k_onconetix.htm">July 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024061151/ea0209387-8k_onconetix.htm">July 15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024066108/ea0210771-8k_onconetix.htm">August 7, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075008/ea0213181-8k_onconetix.htm">September 3, 2024</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075697/ea0213522-8k_onconetix.htm">September 5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024077457/ea0214181-8k_onconetix.htm">September 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024080705/ea0215265-8k_onconetix.htm">September 20, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea0215560-8k_onconetix.htm">September 24, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea0216649-8k_onconetix.htm">October 3, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024086655/ea0217249-8ka1_onconetix.htm">October 9, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024089338/ea0218143-8k_onconetix.htm">October 21, 2024</A>;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Definitive Proxy Statement,
as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024064077/ea0210311-def14a_onconetix.htm">August 1, 2024</A>, and the <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075010/ea0213181-8k_onconetix.htm">supplemental proxy materials</A> filed with the SEC on September 3, 2024; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our securities
registered under Section 12 of the Exchange Act as filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex4-2_onconetix.htm">Exhibit 4.2</A> on our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea0201701-10k_onconetix.htm">Form 10-K</A> for the year ended December
31, 2023, as filed with the SEC on April 11, 2024.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You may request a copy of
these filings, at no cost, by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Onconetix, Inc.<BR>
201 E. Fifth Street, Suite 1900<BR>
Cincinnati, Ohio 45202<BR>
(513) 620-4101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You may also access the documents
incorporated by reference in this prospectus through our website at <I>www.onconetix.com</I>. Except for the specific incorporated documents
listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration
statement of which it forms a part. The information contained on our website is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II<BR>
INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Set forth below are estimates
(except in the case of SEC registration fees) of the amount of fees and expenses to be incurred in connection with the issuance and distribution
of the offered securities, other than underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 89%; padding-left: 10.25pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,884.98</FONT></TD>
    <TD STYLE="width: 1%"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10.25pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10.25pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10.25pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10.25pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,884.98</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 145 of the DGCL inter
alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that
such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys&rsquo; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding
if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized
for such persons against expenses (including attorneys&rsquo; fees) actually and reasonably incurred in connection with the defense or
settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction
otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized
in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written
opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 145 further authorizes
a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or
not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers and
directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 102(b)(7) of the
DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of
a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such
provision shall not eliminate or limit the liability of a director (i) for any breach of the director&rsquo;s duty of loyalty to the corporation
or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv) for
any transaction from which the director derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 6 of the bylaws of
the Company contains provisions which are designed to provide mandatory indemnification of directors and officers of the Company to the
full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the extent required by the
DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification will only be made upon
delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately
determined that such director is not entitled to indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Incorporated by Reference</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 8%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 57%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex2-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Share Exchange Agreement, dated December 15, 2023, by and among the Company, Proteomedix, Thomas Meier and the Sellers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022009250/ea156152ex3-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February 23, 2022.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">February 24. 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023031827/ea177344ex3-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Company&rsquo;s Second Amended and Restated Certificate of Incorporation</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 24, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex3-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Company&rsquo;s Second Amended and Restated Certificate of Incorporation.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex3-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Fourth Amended and Restated Bylaws of the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024080508/ea021523201ex3-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">September 20, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea021556001ex3-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">September 24, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex4-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Specimen Common Stock Certificate.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex4-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Description of Registered Securities.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204ex3-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Certificate of Designation of Series A Preferred Stock.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex4-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Certificate of Designation of Series B Convertible Preferred Stock.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023062922/ea182728ex4-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Inducement PIO.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 3, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024060635/ea020927701ex4-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Inducement PIO. &nbsp;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">July 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea021556001ex4-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Altos Warrants.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">September 24, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex4-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Warrant.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.9 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex3-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Certification of Designation of Series C Preferred Stock.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">5.1** &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Opinion of Ellenoff Grossman &amp; Schole LLP as to the legality of the securities being registered.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">2019 Equity Incentive Plan.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">2022 Equity Incentive Plan.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 29, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-3_bluewater.htm"><FONT STYLE="font-size: 10pt">2019 Equity Incentive Plan Form of Stock Option Grant Agreement.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-4_bluewater.htm"><FONT STYLE="font-size: 10pt">2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-5_bluewater.htm"><FONT STYLE="font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-6_bluewater.htm"><FONT STYLE="font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-7_bluewater.htm"><FONT STYLE="font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 6, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-11_bluewater.htm"><FONT STYLE="font-size: 10pt">Lease Agreement, dated as of April 29, 2021, between the Registrant and Regus Management Group, LLC.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-12_bluewater.htm"><FONT STYLE="font-size: 10pt">Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of July 19, 2019.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 57%"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-13_bluewater.htm"><FONT STYLE="font-size: 10pt">Project Addendum 1 to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of October 9, 2019.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-14_bluewater.htm"><FONT STYLE="font-size: 10pt">Letter Agreement between the Registrant and Ology Bioservices, Inc., dated as of January 9, 2020.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-15_bluewater.htm"><FONT STYLE="font-size: 10pt">Project Addendum II to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of May 21, 2021</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-16_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Joseph Hernandez</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-17_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Erin Henderson</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-18_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Jon Garfield.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 8, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Neil Campbell.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Bruce Harmon.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-21_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Ralph Schiess.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-22_onconetix.htm"><FONT STYLE="font-size: 10pt">Amendment to Employment Agreement, dated October 15, 2020, by and between Proteomedix and Ralph Schiess.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-23_onconetix.htm"><FONT STYLE="font-size: 10pt">Amendment to Employment Agreement by and between Proteomedix and Ralph Schiess.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-24_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Employment Agreement with Christian Br&uuml;hlmann.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.22</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-25_onconetix.htm"><FONT STYLE="font-size: 10pt">Amendment to Employment Agreement, dated October 16, 2020, by and between Proteomedix and Christian Br&uuml;hlmann.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-26_onconetix.htm"><FONT STYLE="font-size: 10pt">Amendment to Employment Agreement by and between Proteomedix and Christian Br&uuml;hlmann.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex99-1_bluewater.htm"><FONT STYLE="font-size: 10pt">General Release of Claims, dated October 5, 2023, by and between Jon Garfield and the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591ex99-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Release, dated January 10, 2024, by and between the Company and Dr. Neil Campbell.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 12, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-3_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Indemnification Agreement for Directors and Officers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.27</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022020636/ea158617ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 19, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022020636/ea158617ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Registration Rights Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 19, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022046943/ea164234ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 11, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022046943/ea164234ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Registration Rights Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 11, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022072376/f10q0922ex10-3_bluewater.htm"><FONT STYLE="font-size: 10pt">Settlement Agreement and Release, dated October 9, 2022, by and between the Registrant and Boustead Securities, LLC.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 14, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022026516/f10q0322ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Amendment No. 1 to Project Addendum 2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 13, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">10.33</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 57%"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022026516/f10q0322ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022, by and between the Registrant and St. Jude Children&rsquo;s Research Hospital, Inc.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">May 13, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023039141/f10q0323ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Patent &amp; Technology License Agreement, dated November 18, 2022, between the Company and the University of Texas Health Science Center at San Antonio.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 12, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.35</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023039141/f10q0323ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Co-Development Agreement, dated February 1, 2023, between the Company and AbVacc, Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 12, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.36</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023024177/ea175921ex1-1_bluewater.htm"><FONT STYLE="font-size: 10pt">At-the-Market Offering Agreement, dated March 29, 2023, between the Company and H.C. Wainwright &amp; Co., LLC.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 29, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated April 19, 2023, between the Company and Veru Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 20, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.38</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Amendment to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390023031189/ea177216-8k_bluewater.htm">Form of Non-Competition and Non-Solicitation Agreement, dated April 19, 2023.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 20, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, and the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 14, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.41</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344ex10-2_bluewater.htm"><FONT STYLE="font-size: 10pt">Management Services Agreement, dated June 13, 2023, by and among WraSer, Xspire and the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 14, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.42</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000101376223005521/f10q0623ex10-14_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 20, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.43</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023088387/f10q0923ex10-6_bluewater.htm"><FONT STYLE="font-size: 10pt">Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 17, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.44</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Lock-Up Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.45</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Non-Competition and Non-Solicitation Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-3_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Stockholder Support Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and certain stockholders of Proteomedix</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-4_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Subscription Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and the PMX Investor.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 21, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.48</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 19, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.49</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886ex10-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 19, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024007414/ea192391ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Debenture, dated January 23, 2024 issued to the PMX Investor</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">January 29, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.51</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement, dated January 4, 2024, by and between the Company and Thomas Meier.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">February 12, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">10.52</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 57%"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-55_onconetix.htm"><FONT STYLE="font-size: 10pt">License Agreement, dated March 27, 2023, between Proteomedix and Laboratory Corporation of America Holdings.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">10.55</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023061642/ea182607ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Inducement Letter</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 1, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.54</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390023062922/ea182728ex10-1_bluewater.htm"><FONT STYLE="font-size: 10pt">Form of Letter Agreement.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 3, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea020475101ex10-2_oncone.htm"><FONT STYLE="font-size: 10pt">Amendment to Debenture, dated April 24, 2024, issued to the PMX Investor.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 26, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea020475101ex10-1_oncone.htm"><FONT STYLE="font-size: 10pt">Forbearance Agreement, dated April 24, 2024, by and between the Company and Veru Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 26, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024049815/ea020378801ex10-60_onconetix.htm"><FONT STYLE="font-size: 10pt">Master Research Services Agreement, dated October 1, 2022, by and between Proteomedix AG and Immunovia, AB</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.60</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 25, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.58</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024049815/ea020378801ex10-61_onconetix.htm"><FONT STYLE="font-size: 10pt">Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.61</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 25, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024049815/ea020378801ex10-62_onconetix.htm"><FONT STYLE="font-size: 10pt">Amendment No. 1, dated June 26, 2023, to Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.62</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 25, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/ea020763501ex99-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Release Agreement, dated June 10, 2024, between the Company and Bruce Harmon.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 13, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052976/ea020793301ex10-1_onconet.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement, dated June 10, 2024, between the Company and Karina Fedasz.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 14, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024060635/ea020927701ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Inducement Letter</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">July 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024080705/ea021526501ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Forbearance Agreement between the Company and Veru, dated September 19, 2024</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">September 20, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex10-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement dated October 2, 2024 relating to the sale of the Series C Preferred Stock and Warrants</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.65</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex10-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of Registration Rights Agreement dated as of October 2, 2024 relating to the resale of the shares of Common Stock underlying the Series C Preferred Stock and Warrants</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.66</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex10-3_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of ELOC Purchase Agreement dated October 2, 2024</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.67</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex10-4_onconetix.htm"><FONT STYLE="font-size: 10pt">Form of ELOC Registration Rights Agreement dated October 2, 2024</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">16 &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024089338/ea0218143-8kex16i_onconetix.htm"><FONT STYLE="font-size: 10pt">Letter from EisnerAmper LLP, dated October 21, 2024.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 21, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex-21_onconetix.htm"><FONT STYLE="font-size: 10pt">List of Subsidiaries.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021874601ex23-1_onconetix.htm"><FONT STYLE="font-size: 10pt">Consent of CBIZ CPAs P.C.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021874601ex23-2_onconetix.htm"><FONT STYLE="font-size: 10pt">Consent of EisnerAmper LLP.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.3*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021874601ex23-3_onconetix.htm"><FONT STYLE="font-size: 10pt">Consent of BDO AG.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">23.4** &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Ellenoff Grossman &amp; Schole (included as part of Exhibit 5.1 hereto).</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">24* &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Power of Attorney (included on signature page to this Registration Statement).</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">107* &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021874601ex-fee_onconetix.htm"><FONT STYLE="font-size: 10pt">Filing Fee Table.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">**</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To be filed by amendment.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&dagger;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certain of the exhibits and
schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of
all omitted exhibits and schedules to the SEC upon its request.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">#</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certain portions of this exhibit
(indicated by &ldquo;[*]&rdquo; have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as we have determined they (1) are
not material and (2) are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy
of any omitted portion to the SEC upon request.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If the registrant is relying
on Rule 430B:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each prospectus filed by the
registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each prospectus required to
be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities
Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus.
As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such effective date; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If the registrant is subject
to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Cincinnati, Ohio, on November  1, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>ONCONETIX, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%"><FONT STYLE="font-size: 10pt">/s/ Karina M. Fedasz</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Karina M. Fedasz</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">KNOW ALL PERSONS BY THESE
PRESENTS that each individual whose signature appears below hereby constitutes and appoints each of Ralph Schiess and Karina M. Fedasz
as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place
and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement,
and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing
pursuant to Rule 462(b) promulgated under the Securities Act of 1933 increasing the number of shares for which registration is sought,
and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith,
making such changes in this registration statement as such attorney-in-fact and agent so acting deem appropriate, with the SEC, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to
be done with respect to the offering of securities contemplated by this registration statement, as fully to all intents and purposes as
he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his, her or their
substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ralph Schiess</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November  1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ralph Schiess</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Karina M. Fedasz</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November  1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Karina M. Fedasz</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James Sapirstein</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November  1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Sapirstein</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas Meier</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">November 1, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Meier</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Timothy Ramdeen</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November  1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy Ramdeen</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ajit Singh</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">November 1, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit Singh</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Simon Tarsh</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November  1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Tarsh</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>





















































































</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "ea0218746-s1_onconetix.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 395087}]
{"company-data": {"conformed-name": "Onconetix, Inc.", "cik": "0001782107", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-282958", "film-number": "241419924"}, "business-address": {"street1": "201 E. FIFTH STREET", "street2": "SUITE 1900", "city": "CINCINNATI", "state": "OH", "zip": "45202", "phone": "513-620-4101"}, "mail-address": {"street1": "201 E. FIFTH STREET", "street2": "SUITE 1900", "city": "CINCINNATI", "state": "OH", "zip": "45202"}, "former-company": [{"former-conformed-name": "Blue Water Biotech, Inc.", "date-changed": "20230424"}, {"former-conformed-name": "Blue Water Vaccines Inc.", "date-changed": "20190710"}]}
As filed with the Securities and Exchange Commission on November
1, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Onconetix, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
2834
83-2262816
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification No.)
201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
Telephone: (513) 620-4101
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Karina M. Fedasz
Interim Chief Financial Officer
201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
Telephone: (513) 620-4101
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
with copies to:
Barry I. Grossman, Esq.
Jessica Yuan, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105
Phone: (212) 370-1300
Fax: (212) 370-7889
Approximate date of commencement
of proposed sale to the public:
From time to time after this registration statement becomes effective.
If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box.
☒
If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
☐
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section
8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities
and Exchange Commission acting pursuant to said Section 8(a), may determine.
The information in
this prospectus is not complete and may be changed. The selling stockholder named in this prospectus may not sell these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these
securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
PROSPECTUS
SUBJECT TO COMPLETION
DATED
NOVEMBER
1
, 2024
6,250,000 Shares of Common Stock
This prospectus relates to
the offer and sale from time to time by Keystone Capital Partners, LLC ("Keystone" or the "Selling Stockholder")
of up to 6,250,000 shares of common stock of Onconetix, Inc. ("we," "us," "our," the "Company,"
or "Onconetix"), par value $0.00001 per share (the "Common Stock"), that have been or may be issued by us to Keystone
pursuant to that certain Common Stock ELOC Purchase Agreement, dated as of October 2, 2024, by and between us and Keystone (the "ELOC
Purchase Agreement"), establishing an equity line of credit. Such shares of our Common Stock include up to 6,250,000 shares of Common
Stock (assuming the shares to be issued are sold at a price of $4.00 per share) that we may elect, in our sole discretion, to issue and
sell to Keystone, from time to time from and after the commencement date under the ELOC Purchase Agreement, and subject to applicable
stock exchange rules.
The actual number of shares
of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to the Selling Stockholder
under the ELOC Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration
statement under the Securities Act of 1933, as amended (the "Securities Act"), with the U.S. Securities and Exchange Commission
(SEC), See "
The Keystone Equity Financing
" for a description of the ELOC Purchase Agreement and "
Selling Stockholder
"
for additional information regarding Keystone.
We are registering the shares
on behalf of the Selling Stockholder, to be offered and sold by it from time to time. We are not selling any securities under this prospectus,
and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus. However, the
actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at
which the shares of our Common Stock are sold. The purchase price per share that Keystone will pay for shares of Common Stock purchased
from us under the ELOC Purchase Agreement will fluctuate based on the market price of our shares at the time we elect to sell shares to
Keystone and, further, to the extent that the Company sells shares of Common Stock under the ELOC Purchase Agreement, substantial amounts
of shares could be issued and resold, which would cause dilution and may impact the Company's stock price.
Our Common Stock is listed
on The Nasdaq Capital Market under the symbol "ONCO." The last reported sale price of our Common Stock on The Nasdaq Capital
Market on October 30, 2024 was $2.96 per share. We recommend that you obtain current market quotations for our Common Stock prior to
making an investment decision.
The Selling Stockholder may
offer all or part of the shares for resale from time to time through public or private transactions, at either prevailing market prices
or at privately negotiated prices. Our registration of the shares of Common Stock covered by this prospectus does not mean that the Selling
Stockholder will offer or sell any of the shares. With regard only to the shares the Selling Stockholder sells for its own behalf, the
Selling Stockholder may be deemed an "underwriter" within the meaning of the Securities Act of 1933, as amended (the "Securities
Act"). The Company has paid all of the registration expenses incurred in connection with the registration of the shares. We will
not pay any of the selling commissions, brokerage fees and related expenses.
We will pay the expenses
incurred in registering the shares, including legal and accounting fees. See "
Plan of Distribution
" on page 28 of
this prospectus.
Investing in our Common
Stock involves certain risks. See "
Risk Factors
" on page 8 of this prospectus, included in any accompanying prospectus
supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider
before deciding to purchase these securities.
We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments
or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is                          , 2024
TABLE OF CONTENTS
Page
ABOUT THIS PROSPECTUS
ii
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
iii
RISK FACTORS
8
PIPE FINANCING
13
ELOC FINANCING
19
DESCRIPTION OF CAPITAL STOCK
25
SELLING STOCKHOLDERS
27
PLAN OF DISTRIBUTION
28
EXPERTS
30
LEGAL MATTERS
30
WHERE YOU CAN FIND MORE INFORMATION
30
i
ABOUT THIS PROSPECTUS
This prospectus is part of
a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") for the delayed
or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix,
Inc. and our Common Stock. The Selling Stockholder may use this registration statement to sell up to an aggregate of up to 6,250,000 shares
of our Common Stock from time to time through any means described in the section entitled "
Plan of Distribution
." Our
registration of the securities covered by this prospectus does not mean that either we or the Selling Stockholder will issue, offer or
sell, as applicable, any of the securities registered hereunder. Under this registration statement, the Selling Stockholder may, from
time to time, sell the securities offered by it described in this prospectus.
We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. However, we will pay the expenses, other than underwriting
discounts and commissions, associated with the sale of shares pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.
We and the Selling Stockholder,
as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained
in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read
both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions
"
Where You Can Find More Information
" and "
Incorporation of Certain Information by Reference
."
No offer of these securities
will be made in any jurisdiction where the offer is not permitted.
You should rely only on the
information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free
writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus
and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other
than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of
an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information
appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus
is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed
materially since those dates.
Unless the context otherwise
indicates, references in this prospectus to "we," "our" and "us" refer, collectively, to Onconetix,
Inc., a Delaware corporation.
Unless otherwise indicated,
all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to the one-for-forty (1:40) reverse
stock split (the "Reverse Stock Split") of all of the outstanding shares of the Company's issued and outstanding Common
Stock on September 24, 2024. As the financial statements incorporated by reference in this prospectus were filed prior to the Reverse
Stock Split, the outstanding shares disclosed in such financial statements are presented on a pre-split basis. Future financial statements
filed by the Company retrospectively present the shares on a post-split basis.
ii
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains
"forward-looking statements" within the meaning of the federal securities laws, and that involve significant risks and uncertainties.
Words such as "may," "should," "could," "would," "predicts," "potential,"
"continue," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications
of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements
are made or management's good faith belief as of that time with respect to future events and are subject to significant risks and
uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions in other documents we file from
time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K.
Important factors that could
cause such differences include, but are not limited to:
●
our projected financial position
and estimated cash burn rate;
●
our estimates regarding expenses,
future revenues and capital requirements;
●
our ability to continue as
a going concern;
●
our need to raise substantial
additional capital to fund our operations;
●
our
ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with
Proteomedix AG ("Proteomedix");
●
our reliance on third parties,
including Labcorp, to develop, market, distribute and sell our products;
●
the successful development
of our commercialization capabilities, including sales and marketing capabilities.
●
our ability to obtain and maintain
the necessary regulatory approvals to market and commercialize our products;
●
the results of market research
conducted by us or others;
●
our ability to obtain and maintain
intellectual property protection for our current products;
●
our ability to protect our
intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual
property rights;
●
the possibility that a third
party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights
and that we may incur substantial costs and be required to devote substantial time defending against claims against us;
●
our reliance on third parties,
including manufacturers and logistics companies;
●
the success of competing therapies
or diagnostics and products that are or become available;
●
our ability to successfully
compete against current and future competitors;
iii
●
our ability to expand our organization
to accommodate potential growth and our ability to attract, motivate and retain key personnel;
●
the potential for us to incur
substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause
us to limit our commercialization of our products;
●
market acceptance of our products,
the size and growth of the potential markets for our current products, and our ability to serve those markets; and
●
disruptions in the business
of the Company or Proteomedix, which could have an adverse effect on their respective businesses and financial results.
These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in "
Risk Factors
." Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected
in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations.
You should read this prospectus
and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which
this prospectus forms a part with the understanding that our actual future results, levels of activity, performance and events and circumstances
may be materially different from what we expect.
iv
PROSPECTUS SUMMARY
The SEC allows us to "incorporate
by reference" certain information that we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we
file later with the SEC will update automatically, supplement and/or supersede the information disclosed in this prospectus. Any statement
contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is
deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the following summary
together with the more detailed information regarding our company, our Common Stock and our financial statements and notes to those statements
included in this prospectus.
Our Company
We are a commercial stage
biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology.
Through our recent acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed
by Proteomedix and approved for sale in the European Union ("EU") under the In Vitro Diagnostic Regulation ("IVDR"),
which we anticipate will be marketed in the U.S. as a lab developed test ("LDT") through our license agreement with Labcorp.
We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia
("BPH"), a disorder of the prostate. ENTADFI has not generated any revenue from product sales, and Proclarix has generated
only minimal amounts of development revenue since its acquisition.
Proclarix is an easy-to-use
next generation protein-based blood test that can be done with the same sample as a patient's regular Prostate-Specific Antigen
("PSA") test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA molecules
in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons
including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing for many patients
and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis
and overtreatment that impacts the physician's routine, our healthcare system, and the quality of patients' lives. Approximately
10% of all men have elevated PSA levels, commonly referred to as the diagnostic "grey zone", of which only 20 - 40% present
clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult to decide if a biopsy is necessary
to verify a potential clinically significant cancer diagnosis.
Proclarix helps doctors and
patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic
support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories
can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked immunosorbent assay
("ELISA") standard, which most diagnostic laboratories are already equipped to process.
Since our inception in October
2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development,
undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel,
acquiring and developing the technology of our vaccine candidates, organizing and staffing our company, performing business planning,
establishing our intellectual property portfolio and raising capital to support and expand such activities. Following our April 2023 acquisition
of ENTADFI, we shifted our business strategy towards the field of men's health and oncology and deprioritized our preclinical vaccine
programs. Since that time, we have sought to build assets in therapeutics, diagnostics, and clinician services for men's health
and oncology.
1
In light of (i) the time
and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company's cash runway and indebtedness, the
Company determined to pause its commercialization of ENTADFI during the first quarter of 2024, as it explores strategic alternatives to
monetize ENTADFI, such as a potential sale of the ENTADFI assets. To that end, the Company engaged an investment advisor to assist with
a potential sale or other transaction of the ENTADFI assets during the second quarter of 2024. There is currently no plan to resume commercialization
of ENTADFI, and as such, if we are not able to consummate a sale or other transaction of the ENTADFI assets, we may abandon the assets
and destroy our inventory of the product. In addition, as part of cost reduction efforts and in connection with our initial pause in commercializing
ENTADFI, we terminated three employees involved with the ENTADFI program, effective April 30, 2024, with such individuals to continue
assisting the Company on an as-needed, consulting basis. Based on the current circumstances surrounding ENTADFI, at June 30, 2024, the
ENTADFI assets were fully impaired.
We are currently focusing
our efforts on commercializing Proclarix.
Proclarix was first CE marked
under the IVD Directive in Europe in January 31, 2019. On October 7, 2022, Proclarix gained CE marking under the IVDR and was registered
in the United Kingdom and Switzerland under applicable regulations. Given Proclarix is CE-marked for sale in the European Union, we expect
to generate revenue from sales of Proclarix by 2025. Although we anticipate these sales to offset some expenses relating to commercial
scale up and development, we expect our expenses will increase substantially in connection with our ongoing activities, as we:
●
commercialize Proclarix;
●
hire additional personnel;
●
operate as a public company;
and
●
obtain, maintain, expand and
protect our intellectual property portfolio.
We rely and will continue
to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and we will continue to rely
on third parties, of which the main suppliers are single-source suppliers, for commercial products.
We do not have any products
approved for sale, aside from Proclarix in the EU, from which we have generated only minimal amounts of development revenue since its
acquisition, and ENTADFI, from which we have not generated any revenue from product sales, and for which we have now abandoned commercialization
activities. To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the
initial public offering ("IPO"), private placements, the proceeds received from warrant exercises and an issuance of debt
in January 2024. We will continue to require significant additional capital to commercialize Proclarix, and to fund operations for the
foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs
through public or private equity or debt financings, third-party (including government) funding and to rely on third-party resources for
marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination
of these approaches, to support our operations.
We have incurred net losses
since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from
quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing
activities, our expenditures on other research and development activities and commercialization activities. As of June 30, 2024, the Company
had a working capital deficit of approximately $18.6 million and an accumulated deficit of approximately $82.2 million. We will need to
raise additional capital within the next 12 months to sustain operations.
Until we generate revenue
sufficient to support self-sustaining cash flows, if ever, we will need to raise additional capital to fund our continued operations,
including our product development and commercialization activities related to our current and future products. There can be no assurance
that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide
self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The consolidated
financial statements of Onconetix, which are incorporated by reference in this prospectus, do not include any adjustment that might be
necessary if the Company is unable to continue as a going concern.
2
Because of the numerous risks
and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will
be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix, we may not become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and may be forced to reduce our operations.
Recent Developments
PIPE Financing and ELOC
On
October 2, 2024, the Company entered into, and sold to six institutional investor(s) (collectively, the "PIPE Investors"),
pursuant to a securities purchase agreement (the "Securities ELOC Purchase Agreement") an aggregate of 3,499 shares of Series
C convertible preferred stock, par value $0.00001 per share ("Series C Preferred Stock"), which includes an issuance of 830
shares of Series C Preferred Stock to the lead investor as consideration for the PIPE Investors' irrevocable commitment to purchase
shares of the Series C Preferred Stock, and warrants to purchase 591,856 shares of Common Stock at an initial exercise price of $4.38,
subject to adjustment (the "PIPE Warrants" and, together with the Series C Preferred Stock, the "PIPE Securities"),
for aggregate cash proceeds to the Company of $2.0 million. Such investment is referred to as the "PIPE Financing." Concurrently
with entering into the Securities ELOC Purchase Agreement, the Company also entered into a registration rights agreement with the PIPE
Investors, pursuant to which it has agreed to provide the PIPE Investors with certain registration rights related to the shares of Common
Stock underlying the PIPE Securities.
On October 2, 2024, the Company
also entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility (the "ELOC Purchase Agreement")
with Keystone, whereby the Company may offer and sell, from time to time at its sole discretion, and whereby Keystone has committed to
purchase, up to $25.0 million of the Company's newly issued Common Stock, subject to the limitations described herein. Concurrently
with entering into the ELOC Purchase Agreement, the Company also entered into a registration rights agreement with Keystone, pursuant
to which it agreed to provide Keystone with certain registration rights related to the shares issued under the ELOC Purchase Agreement
(the "ELOC Registration Rights Agreement").
Reverse Stock Split
On September 23, 2024, the
Company filed an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation to effect
a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40).
The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on September 24, 2024
(the "Effective Time"). The Company's Common Stock continued to be traded on The Nasdaq Capital Market under the symbol
ONCO and began trading on a split-adjusted basis when the market opened on Tuesday, September 24, 2024, under a new CUSIP number, 68237Q104.
At the Effective Time, every
40 shares of the Company's issued and outstanding Common Stock were converted automatically into one issued and outstanding share
of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and without any change in the par
value per share.
Conversion of Series A Preferred Stock
On September 24, 2024, the
Company issued an aggregate of 142,749 post-Reverse Stock Split shares of Common Stock to Veru Inc. ("Veru"), following Veru's
election to convert all of the 3,000 shares of Series A preferred stock ("Series A Preferred Stock") of the Company issued
to it on September 29, 2023. The Series A Preferred Stock was originally issued to Veru pursuant to an Amendment to Asset Purchase Agreement,
dated September 29, 2023, between the Company and Veru.
Conversion of Series B Preferred Stock
On September 24, 2024, the
Company issued an aggregate of 6,741,820 post-Reverse Stock Split shares of Common Stock to certain stockholders of the Company (the "PMX
Converted Shares") who were formerly holders of outstanding capital stock or convertible securities (the "Sellers")
of Proteomedix AG ("Proteomedix"), pursuant to the automatic conversion of all the 2,696,729 shares of Series B preferred
stock ("Series B Preferred Stock") of the Company, which Series B Preferred Stock was originally issued to the Sellers on
December 15, 2023. The Series B Preferred Stock was originally issued to the Sellers pursuant to a Share Exchange Agreement, dated December
15, 2023, between the Company, Proteomedix and the Sellers (the "Share Exchange Agreement"), and were subject to automatic
conversion following (i) the Company's receipt of stockholder approval for the issuance of the PMX Converted Shares and (ii) the
effectiveness of the Reverse Stock Split, which provided for a sufficient number of authorized shares to issue the PMX Converted Shares,
as contemplated by the Share Exchange Agreement.
3
Altos Units
On September 24, 2024, pursuant
to the Subscription Agreement, dated
December 18, 2023, between the Company and Altos Venture
AG ("Altos" and such agreement, the "Subscription Agreement"), the Company issued an aggregate of 513,424 units
(the "Units") to Altos, each Unit comprised of (i) one share of Common Stock and (ii) one pre-funded warrant (collectively,
the "Altos Warrants") to purchase 0.3 shares of Common Stock at an exercise price of $0.04 per share. The Altos Warrants were
immediately exercisable at any time on or after the date of issuance and had a term of exercise of five (5) years from the date of
issuance. Additional shares are issuable to Altos to the extent Altos continues to hold Common Stock included in the Units and if
the VWAP during the 270 days following closing is less than $10.00, as set forth in the Subscription Agreement.
On
September 24, 2024, Altos exercised all of the Altos Warrants, and the Company issued to Altos an additional 154,027 shares of Common
Stock upon such exercise.
Veru Agreement
Previously, on April 19, 2023,
the Company entered into an asset purchase agreement with Veru (the "Veru APA"). Pursuant to the terms of the Veru APA, the
Company agreed to provide Veru with initial consideration totaling $20.0 million, consisting of (i) $6.0 million paid upon the closing
of the transaction, (ii) an additional $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023, and
(iii) an additional $10.0 million in the form of two equal (i.e. each for $5.0 million) non-interest bearing notes payable, each due on
April 19, 2024 (the "April Veru Note") and September 30, 2024 (the "September Veru Note"). On September 29, 2023,
the Company entered into an amendment (the "Veru Amendment") of the Veru APA. Pursuant to the Veru Amendment, the $4.0 million
note payable originally due on September 30, 2023, was deemed paid and fully satisfied upon (1) the payment to Veru of $1 million in immediately
available funds on September 29, 2023, and (2) the issuance to Veru by October 3, 2023, of 3,000 shares of Series A Preferred Stock of
the Company. Previously, on April 24, 2024, the Company entered into a Forbearance Agreement with Veru (the "Original Forbearance
Agreement"). Pursuant to the Original Forbearance Agreement, Veru agreed, among other things, to forbear from exercising its rights
and remedies under the April Veru Note until March 31, 2025 (the "April 2024 Forbearance Period").
On September 19, 2024,
the Company entered into an Amended and Restated Forbearance Agreement with Veru (the "A&R Forbearance Agreement") which
amends and restates the Original Forbearance Agreement in its entirety. Pursuant to the A&R Forbearance Agreement, Veru will forbear
from exercising its rights under both the April Veru Note and the September Veru Note, subject to the terms and conditions set forth below.
Pursuant
to the A&R Forbearance Agreement, the April 2024 Forbearance Period continues to end on the earlier of (a) March 31, 2025
and (b) the occurrence of an Event of Default (as defined in the A&R Forbearance Agreement). The A&R Forbearance Agreement
also extends the due date for the
September Veru Note until the earlier to occur of: (i) June 30, 2025 or (ii) the occurrence
of any Event of Default.
The A&R Forbearance Agreement also effected certain modifications
to the payment terms in the Original Forbearance Agreement and amended certain terms of the September Veru Note as summarized below.
Pursuant
to the A&R Forbearance Agreement, the Company agreed to make the following required payments (the "Required Payments")
during the April 2024 Forbearance Period first to accrued and unpaid interest under the April Veru Note and then any remainder to the
outstanding principal amount of the April Veru Note:
●
Interest at the rate of 10%
per annum shall accrue on any unpaid principal balance of the April Veru commencing on April 20, 2024 through the date that the outstanding
principal balance under the April Veru Note is paid in full;
4
●
monthly payments equal to 25%
(increased from 15% in the Original Forbearance Agreement) of (i) the monthly cash receipts of Proteomedix for the licensing or sale
of any products or services, (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix anywhere
in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries for milestone payments or royalties from Labcorp
cash receipts of the Company or its subsidiaries from certain sale or licensing revenues or payments (the Ordinary Cash Revenue"),
which increased amount shall begin on October 20, 2024 for cash receipts in September 2024;
●
payment of 20% (increased from
10% in the Original Forbearance Agreement) of the net proceeds from certain financing or other transactions outside the ordinary course
of business completed by the Company or any of its subsidiaries during the April 2024 Forbearance Period, which increased amount will
begin for any net proceeds received after September 19, 2024;
●
15% of the Ordinary Cash Revenue
generated in August 2024 shall be due to Veru on September 26, 2024 (the "September Veru Payment"); and
●
The remaining balance of the
April Veru Note will be due at the end of the April 2024 Forbearance Period.
The
Company and Veru also agreed to the following amendments to the September Veru Note in the A&R Forbearance Agreement:
●
As noted above, an extension of the maturity date to June 30, 2025;
●
The accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September Veru Note commencing on October 1, 2024 through the date that the outstanding principal balance under the September Veru Note is paid in full;
●
Any amounts owed on the September Veru Note, including but not limited to unpaid principal and accrued interest, will be paid in cash or, upon the mutual written consent of Veru and the Company, in shares of the Company's Common Stock or a combination of cash and the Company's Common Stock;
●
Following full repayment of all principal and interest under the April Veru Note, the Company will make the Required Payments first towards accrued and unpaid interest under the September Veru Note and then towards the remaining principal balance payable under the September Veru Note;
●
If the aggregate unpaid principal outstanding under the April Veru Note and the September Veru Note and all accrued and unpaid interest thereon is repaid in cash on or before December 31, 2024, then the total principal balance under the September Veru Note that will be payable by the Company in satisfaction of its obligations under the September Veru Note will be reduced from $5,000,000 to $3,500,000.
On September 26, 2024, Veru and the Company entered
into a waiver agreement, pursuant to which Veru postponed the Company's obligation to make the September Veru Payment until the
earlier of (i) the date upon which the Company consummates a financing transaction in which it raises gross proceeds of greater or equal
to $1,000,000 and (ii) October 4, 2024. The Company paid the September Veru Payment on October 10, 2024.
5
Warrant Inducement
On July 11, 2024, the Company,
entered into common stock preferred investment options exercise inducement offer letters (the "Inducement Letter") with certain
holders of existing preferred investment options to purchase shares of the Company's common stock at the original exercise prices
of $101.84 and $43.60 per share, issued on August 11, 2022 and August 2, 2023, respectively, pursuant to which the holders agreed to exercise
for cash such existing preferred investment options to purchase an aggregate of 186,465 of the Company's common stock, at a reduced
exercise price of $6.00 per share, in consideration for the Company's agreement to issue new preferred investment options (the "PIOs")
to purchase up to an aggregate of 559,397 shares of the Company's common stock.
The transaction closed on
July 12, 2024 and the Company received aggregate net proceeds of approximately $0.9 million from the exercise of the existing preferred
investment options by the holders and the sale of the Inducement PIOs, after deducting placement agent fees and other offering expenses
payable by the Company.
The Company engaged H.C.
Wainwright & Co., LLC ("Wainwright") to act as its exclusive placement agent in connection with the Warrant Inducement
and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the existing preferred investment options
as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the existing preferred investment options, plus the
reimbursement of up to $85,000 in certain expenses. The Company also agreed to (i) issue to Wainwright or its designees an aggregate of
13,054 preferred investment options, and (ii) upon any exercise for cash of the Inducement PIOs, 7.5% of the aggregate exercise price
and such number of warrant to purchase shares of common stock equal to 7.0% of the aggregate number of such shares of common stock underlying
the Inducement PIOs that have been exercised, which warrants will have substantially the same terms as the Placement Agent Inducement
PIOs.
The Inducement PIOs have
an initial exercise price of $6.00 per share, subject to adjustment; one-third of such preferred investment options will expire five years
from the date of stockholder approval (September 5, 2024), and the remaining two-thirds will expire twenty-four months from such date.
The Placement Agent Inducement PIOs have an initial exercise price of $7.50 per share, subject to adjustment, and will expire five years
from the issuance date.
In addition, per the terms
of the Inducement Letter, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any other
registration statement with the SEC (in each case, subject to certain exceptions) until the later of (i) the filing of a definitive proxy
statement on Schedule 14A for the purpose of obtaining the requisite stockholder approval and (ii) 30 days after the closing date. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letter) until six months
after the closing date (subject to certain exceptions).
6
ABOUT THIS OFFERING
Common Stock outstanding prior to this offering
8,294,734 shares
Shares of Common Stock offered by the Selling Stockholder
Up to 6,250,000 shares of Common Stock (assuming the shares to be issued are sold at a price of $4.00 per share)
Common Stock to be outstanding after this offering
14,544,734 shares (assuming the issuance of all shares of Common Stock issuable under the ELOC Purchase Agreement)
Use of proceeds
We are not selling any securities under this prospectus,
    and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
    up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
    of our Common Stock pursuant to the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone
    may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common
    Stock are sold.
Pursuant to the ELOC Purchase Agreement, 30% of
    the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of the Company's
    Series C Preferred Stock.
Pursuant to the Amended and Restated Forbearance
    Agreement, dated September 19, 2024, between the Company and Veru, we are required to pay to Veru 20% of the net proceeds received from
    any sale of Common Stock under the ELOC Purchase Agreement to pay down our obligations to Veru.
Terms of this offering
The Selling Stockholder, including its transferees, donees, pledgees, assignees, and successors-in-interest, may sell, transfer, or otherwise dispose of any or all of the shares of Common Stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. The shares of Common Stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices.
Nasdaq symbol
Our Common Stock is listed on The Nasdaq Capital Market under the symbol "ONCO."
Risk Factors
Investing in our securities involves significant risks. Before making a decision whether to invest in our securities, please read the information contained in or incorporated by reference under the heading "
Risk Factors
" in this prospectus, the documents we have incorporated by reference herein and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus. See "
Incorporation of Certain Information by Reference
" and "
Where You Can Find More Information
."
7
RISK FACTORS
Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus, in our most recent
Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that
we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, before making
an investment decision pursuant to this.
Our business, financial condition
and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties
not presently known to us or that we currently deem immaterial that may adversely affect us in the future.
Risks Related to This Offering
It is not possible to predict the actual number of shares
of our Common Stock, if any, we will sell under the ELOC Purchase Agreement, or the actual gross proceeds resulting from those sales or
the dilution to you from those sales. Further, we may not have access to the full amount available under the ELOC Purchase Agreement.
Pursuant to the ELOC Purchase Agreement, Keystone
shall purchase from us up to the lesser of (i) $25.0 million in shares of our Common Stock and (ii) 1,658,525 shares, representing 19.99%
of the total number of shares of Common Stock outstanding immediately prior to the execution of the ELOC Purchase Agreement (the "Exchange
Cap"), upon the terms and subject to the conditions and limitations set forth in the ELOC Purchase Agreement (the "Keystone
Commitment Amount"); provided, however, that such limitations will not apply if we obtain stockholder approval to issue additional
shares of Common Stock. On October 11, 2024 the Company obtained stockholder approval to issue shares to Keystone in excess of the Exchange
Cap. Accordingly, we have reserved 6,250,000 shares for issuance under the ELOC Purchase Agreement and resale pursuant to this prospectus.
The shares of our Common Stock that may be issued under the ELOC Purchase Agreement may be sold by us to Keystone at our discretion from
time to time from the Commencement Date (as defined below) until the earliest to occur of (i) the 36-month anniversary of the effective
date of the registration statement of which this prospectus forms a part, (ii) the date on which Keystone has purchased the Keystone Commitment
Amount pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock fails to be listed or quoted on Nasdaq or any
successor Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date on which, pursuant to or within the meaning of
any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for
the benefit of our creditors.
We generally have the right to control the timing
and amount of any sales of our Common Stock to Keystone under the ELOC Purchase Agreement. Sales of our Common Stock, if any, to Keystone
under the ELOC Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide
to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant to the ELOC Purchase
Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Keystone Commitment Amount or how much in proceeds
we may obtain under the ELOC Purchase Agreement. If we cannot sell securities under the Keystone Equity Financing, we may be required
to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity
and cash position.
Because the purchase price per share of Common
Stock to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement, if any, will
fluctuate based on the market prices of our Common Stock at the time we make such election, it is not possible for us to predict, as of
the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to Keystone under the
ELOC Purchase Agreement, the purchase price per share that Keystone will pay for shares of Common Stock purchased from us under the ELOC
Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Keystone under the ELOC Purchase Agreement.
We are registering 6,250,000 shares of our Common Stock under this
prospectus. As of October 30, 2024, there were 8,294,734 shares of Common Stock outstanding. If all of the 6,250,000 shares of our Common
Stock offered for resale by the Selling Stockholder under this prospectus were issued and outstanding as of October 30, 2024, such shares
would represent approximately 42.97% of total number of shares of our Common Stock outstanding.
8
The actual number of shares of our Common Stock
Issuable will vary depending on the then current market price of shares of our Common Stock sold to the Selling Stockholder in this offering
and the number of shares of our Common Stock we ultimately elect to sell to the Selling Stockholder under the ELOC Purchase Agreement.
If it becomes necessary for us to issue and sell to Keystone under the ELOC Purchase Agreement more than the 6,250,000 shares of our Common
Stock (assuming the shares are sold at a price of $4.00 per share) being registered for resale under this prospectus in order to receive
aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must file with the SEC one or more additional registration
statements to register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock we wish to sell
from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any
additional shares of our Common Stock under the ELOC Purchase Agreement. Keystone is not obligated to buy any Common Stock under the ELOC
Purchase Agreement if such shares, when aggregated with all other Common Stock then beneficially owned by Keystone and its affiliates
(as calculated pursuant to Section 13(d) of the Securities Exchange Act, and Rule 13d-3 promulgated thereunder), would result in Keystone
beneficially owning Common Stock in excess of 4.99% of the then-outstanding shares of Common Stock. Our inability to access a portion
or the full amount available under the ELOC Purchase Agreement, in the absence of any other financing sources, could have a material adverse
effect on our business or results of operation.
Keystone will pay less than the then-prevailing
market price for our Common Stock, which could cause the price of our Common Stock to decline.
The purchase price of our Common Stock to be sold
to Keystone under the ELOC Purchase Agreement is derived from the market price of our Common Stock on Nasdaq. Shares to be sold to Keystone
pursuant to the ELOC Purchase Agreement will be purchased at a discounted price.
For example, we may effect sales to Keystone pursuant
to a Fixed Purchase Notice (as defined below) at a purchase price equal to the lesser of 90% of (i) the daily VWAP (as defined below)
of the Common Stock for the five trading days immediately preceding the applicable Fixed Purchase Date (as defined below) and (ii) the
closing price of a share of Common Stock on the applicable Fixed Purchase Date during the full trading day on such applicable Purchase
Date. See "
Keystone Committed Equity Financing
" for more information.
As a result of this pricing structure, Keystone
may sell the shares they receive immediately after receipt of such shares, which could cause the price of our Common Stock to decrease.
Investors who buy shares of Common Stock
from Keystone at different times will likely pay different prices.
Pursuant to the ELOC Purchase Agreement, we have
discretion, to vary the timing, price and number of shares of Common Stock we sell to Keystone. If and when we elect to sell shares of
Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone may resell all, some
or none of such shares at any time or from time to time in its sole discretion and at different prices. As a result, investors who purchase
shares from Keystone in this offering at different times will likely pay different prices for those shares, and so may experience different
levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience
a decline in the value of the shares they purchase from Keystone in this offering as a result of future sales made by us to Keystone at
prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares
to Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence
of our arrangements with Keystone may make it more difficult for us to sell equity or equity-related securities in the future at a time
and at a price that we might otherwise wish to effect such sales.
9
Future resales and/or issuances of shares
of Common Stock, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price of our
shares to drop significantly.
The shares of our Common Stock that may be issued
under the ELOC Purchase Agreement may be sold by us to Keystone at our discretion from time to time from the date of effectiveness of
effectiveness of the registration statement of which this prospectus forms a part until the earliest to occur of (i) the 36-month anniversary
of the effective date of the registration statement of which this prospectus forms a part, (ii) the date on which Keystone has purchased
the Aggregate Limit pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock fails to be listed or quoted on
Nasdaq or any successor Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date on which, pursuant to or within
the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general
assignment for the benefit of our creditors.
The purchase price for shares of our Common Stock
that we may sell to Keystone under the ELOC Purchase Agreement will fluctuate based on the trading price of shares of our Common Stock.
Depending on market liquidity at the time, sales of shares of our Common Stock may cause the trading price of shares of our Common Stock
to decrease. We generally have the right to control the timing and amount of any future sales of shares of our Common Stock to Keystone.
Additional sales of shares of our Common Stock, if any, to Keystone will depend upon market conditions and other factors to be determined
by us. We may ultimately decide to sell to Keystone all, some or none of the additional shares of our Common Stock that may be available
for us to sell pursuant to the ELOC Purchase Agreement. If and when we do sell shares of our Common Stock to Keystone, after Keystone
has acquired shares of our Common Stock, Keystone may resell all, some or none of such shares of our Common Stock at any time or from
time to time in its discretion and at different prices. Therefore, sales to Keystone by us could result in substantial dilution to the
interests of other holders of shares of our Common Stock. In addition, if we sell a substantial number of shares of our Common Stock to
Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the shares held by Keystone will represent a significant
portion of our public float and may result in substantial decreases to the price of our Common Stock. The actual sales of shares of our
Common Stock or the mere existence of our arrangement with Keystone may also make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect such sales.
The market price of shares of our Common Stock
could drop significantly if Keystone sells shares of Common Stock or is perceived by the market as intending to sell them. These factors
could also make it more difficult for us to raise additional funds through future offerings of shares of our Common Stock or other securities.
We may use proceeds from sales of our Common
Stock made pursuant to the ELOC Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.
We will have broad discretion over the use of
proceeds from sales of our Common Stock made pursuant to the ELOC Purchase Agreement, including for any of the purposes described in the
section entitled "
Use of Proceeds
," and you will not have the opportunity, as part of your investment decision, to
assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use
of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds
from this offering as set forth in "
Use of Proceeds
," we are not obligated to do so. The failure by us to apply these
funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating
results or enhance the value of our Common Stock.
10
Other Risks
There is substantial
doubt about our ability to continue as a "going concern," and we will require substantial additional funding to finance our
long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate some
or all of our products and operations.
The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future. As of June 30, 2024, the Company had cash of
approximately $0.9 million, a working capital deficit of approximately $18.6 million and an accumulated deficit of approximately
$82.2 million. In addition, as of October 30, 2024, the Company's cash balance was approximately $595,000, and the Company has $5.0
million of debt, plus interest, due in each of March 2025 and June 2025.
We estimate, as of the
date of this prospectus, that our current cash balance is only sufficient to fund our operations into November 2024. We believe that
we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations and
liabilities, and otherwise support the Company's working capital needs and business activities, including making the remaining
payments to Veru and the development and commercialization of Proclarix. Management's plans include generating product revenue
from sales of Proclarix, which is still subject to further successful commercialization activities within certain jurisdictions. In
addition, the Company has now abandoned commercialization activities for ENTADFI and it is exploring strategic alternatives for its
monetization, such as a potential sale of the ENTADFI assets. If we are not able to consummate a sale or other transaction of the
ENTADFI assets, we may abandon the assets and destroy our inventory of the product. Management's plans also include attempting
to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in
place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if
at all. If the Company is unable to secure additional capital, it may be required to delay or curtail any future commercialization
of products, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain
operations and meet its obligations, or, if it is required to, file for bankruptcy. These conditions raise substantial doubt about
the Company's ability to continue as a going concern for a period of time within one year from the issuance of the condensed
consolidated financial statements.
Our future capital requirements
will depend on many factors, including:
●
the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for Proclarix and other products for which we have received or will receive marketing approval;
●
our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;
●
any product liability or other lawsuits related to our products;
●
the expenses needed to attract, hire, and retain skilled personnel;
●
the revenue, if any, received from commercial sales of Proclarix or other products for which we may receive marketing approval;
●
the costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing our patents or other intellectual property rights; and
●
the costs of operating as a public company.
Our ability to raise additional
funds will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional
funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce or terminate our business activities.
11
Our current liabilities
are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors, were to demand payment,
we would be unable to pay.
As of June 30, 2024, we had total current liabilities of approximately
$20.6 million, including accounts payable of approximately $3.2 million, accrued expenses of approximately $1.4 million, and related party
subscription liability of $0.9 million. As of October 30, 2024, the Company's cash balance was approximately $595,000, and the Company
has $5.0 million of debt, plus interest, due in each of March 2025 and June 2025. We are currently considering strategic options for ENTADFI,
including a potential sale or abandonment, and plan to seek funding to support our operations. However, the level of our current liabilities
may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom these payments are due
were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments, we would be subject to
liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency. Under such a scenario,
our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.
We are dependent on third parties, including
Labcorp, to develop, market, distribute and sell our products.
Our ability to receive revenues
is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors. In particular, the development
and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive license agreement that grants
Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix's
intellectual property covered by the license, in the United States for identification, screening, staging, predisposition, diagnosis,
prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not have control over Labcorp's
development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue to advance development and commercialization
efforts, or that Labcorp will successfully commercialize Proclarix in the United States.
Labcorp may terminate or
seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial condition. If Labcorp
terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product development and
commercialization efforts, potentially leading to a loss of revenue and market share.
Additionally, if Labcorp
is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization partner,
or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business,
financial condition, and results of operations.
12
PIPE FINANCING
On
October 2, 2024, the Company entered into, and sold to the PIPE Investors, pursuant to the Securities Purchase Agreement an aggregate
of 3,499 shares of Series C Preferred Stock, which includes an issuance of 830 shares of Series C Preferred Stock to the lead investor
as consideration for the PIPE Investors' irrevocable commitment to purchase shares of the Series C Preferred Stock, and 591,856
PIPE Warrants, for aggregate cash proceeds to the Company of $2.0 million. Concurrently with entering into the Securities Purchase Agreement,
the Company also entered into a registration rights agreement with the PIPE Investors, pursuant to which it has agreed to provide the
PIPE Investors with certain registration rights related to the shares of Common Stock underlying the PIPE Securities.
The
material terms of the Series C Preferred Stock and the PIPE Warrants are set forth below.
Series
C Preferred Stock
Certificate of Designations
General
.
Pursuant
to the Certificate of Designations, the Company has authorized the issuance of up to 10,000 shares of Series C Preferred Stock, each having
a stated value of $1,000 per share (the "Stated Value"). The Company has issued 3,499 shares of the Company Series C
Preferred Stock to the PIPE Investors.
Ranking
.  Except
(i) for the Series A Preferred Stock of the Company (of which there are no shares currently outstanding), which shall be Parity Stock,
and (ii) to the extent that the Required Holders (as defined in the Securities Purchase Agreement) expressly consent to the creation of
Parity Stock or Senior Preferred Stock, all shares of capital stock of the Company will be junior in rank to all Preferred Shares with
respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.
Dividends
. The
holders of Series C Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends
actually paid on shares of Common Stock, when and if actually paid. In addition, from and after the occurrence and during the continuance
of any Triggering Event, dividends ("Default Dividends") will accrue on the Stated Value of each Preferred Share at a rate
of fifteen percent (15.0%) (the "Default Rate") per annum. Default Dividends are payable by way of inclusion of Default Dividends
in the Conversion Amount (as defined below) on each Conversion Date, upon any redemption or upon any required payment upon any Bankruptcy
Triggering Event. In the event that such Triggering Event is subsequently cured (and no other Triggering Event then exists), the accrual
of Default Dividends will cease to be effective as of the calendar day immediately following the date of such cure; provided that Default
Dividends as calculated and unpaid during the continuance of such Triggering Event will continue to apply to the extent relating to the
days after the occurrence of such Triggering Event through and including the date of such cure of such Triggering Event.
Conversion Rights
:
Conversion
at Option of
Holder.  Each holder is entitled to convert any portion of the outstanding Preferred Shares held by such holder
into validly issued, fully paid and non-assessable Conversion Shares at the Conversion Rate. Except as otherwise provided in the Certificate
of Designations, the number of Conversion Shares issuable upon conversion of any Preferred Share will be determined by dividing (x) the
Conversion Amount of such Preferred Share by (y) the Conversion Price (the "Conversion Rate"). As used herein, the term "Conversion
Amount" means, with respect to each Preferred Share, as of the applicable date of determination, the sum of (1) the Stated Value
thereof
plus
(2) any Default Dividends thereon as of such date of determination
plus
(3) any other amounts
owed to such PIPE Investor pursuant to the terms of the Certificate of Designations or any other Transaction Document; and the term "Conversion
Price" means, with respect to each Preferred Share, as of any Conversion Date or other date of determination, $4.5056, subject to
adjustment as provided in the Certificate of Designations.
Conversion
at the Option of the Holder Upon the Occurrence of a Triggering Event
. After the Stockholder Approval Date (as defined in the Securities
Purchase Agreement), if a Triggering Event occurs and is continuing, at any time after the earlier of a holder's receipt of a Triggering
Event Notice and such holder becoming aware of such Triggering Event (such earlier date, the "Alternate Conversion Right Commencement
Date") and ending on the twentieth (20
th
) Trading Day after the later of (x) the date such Triggering Event is cured
and (y) such holder's receipt of a Triggering Event Notice (such ending date, the "Alternate Conversion Right Expiration Date",
and each such period, an "Alternate Conversion Right Period"), such holder may, at such holder's option, by delivery
of a Conversion Notice to the Company (the date of any such Conversion Notice, each an "Alternate Conversion Date"), convert
all, or any number of Preferred Shares held by such holder into shares of Common Stock at the Alternate Conversion Price (each, an "Alternate
Conversion").
13
As used herein:
"Alternate
Conversion Price" means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable Conversion
Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price
and (y) 80% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including the Trading
Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the "Alternate Conversion
Measuring Period"). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion
Measuring Period.
"Alternate
Conversion Floor Amount" means an amount equal to the product obtained by multiplying (A) the higher of (i) the highest price that
the Common Stock trades at on the Trading Day immediately preceding the relevant Alternate Conversion Date and (ii) the applicable Alternate
Conversion Price and (B) the difference obtained by subtracting (i) the number of shares of Common Stock delivered (or to be delivered)
to such holder on the applicable Share Delivery Deadline with respect to such Alternate Conversion from (ii) the quotient obtained by
dividing (x) the applicable Conversion Amount that such holder has elected to be the subject of the applicable Alternate Conversion, by
(y) the applicable Alternate Conversion Price, without giving effect to the Floor Price.
"Floor
Price" means $1.00 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), or,
subject to the rules and regulations of the Principal Market, such lower price as the Company and the Required Holders may agree, from
time to time.
"Triggering
Event Notice" means written notice from the Company delivered to each holder within two Business Days after the occurrence of a
Triggering Event) that includes (i) a reasonable description of the applicable Triggering Event, (ii) a certification as to whether, in
the reasonable opinion of the Company, such Triggering Event is capable of being cured and, if applicable, a reasonable description of
any existing plans of the Company to cure such Triggering Event and (iii) a certification as to the date the Triggering Event occurred
and, if cured on or prior to the date of such Triggering Event Notice, the applicable Alternate Conversion Right Expiration Date.
"Triggering
Event" includes, but is not limited to, the following, subject to certain cure periods as set forth in the Certificate of Designations:
(i) the failure
to file a registration statement for the resale of the shares of Common Stock underlying the Preferred Shares and the PIPE Warrants, or
the failure of the applicable Registration Statement to be declared effective by the SEC, ten (10) days after the applicable deadline;
(ii) the failure
to maintain the effectiveness of a registration statement pursuant to the terms of the Registration Rights Agreement;
(iii) the suspension
from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5)
consecutive Trading Days;
(iv) failure to
cure a Conversion Failure or a Delivery Failure (as defined in the PIPE Warrants) by delivery of the required number of shares of Common
Stock within the requisite time frame;
(v) failure to
maintain authorized, but unissued shares equal to 150% of the shares underlying the Preferred Shares and the PIPE Warrants;
(vi) the occurrence
of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $500,000 of Indebtedness of the Company
or any of its Subsidiaries, or a final judgment or judgments for the payment of money aggregating in excess of $500,000 are rendered against
the Company and/or any of its Subsidiaries;
14
(vii) the institution,
commencement, court order or decree by or against the Company or any Subsidiary of certain bankruptcy, insolvency, reorganization or liquidation
proceedings or other proceedings for the relief of debtors (the "Bankruptcy Triggering Events");
(viii) the Company
and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any
payment with respect to any Indebtedness in excess of $500,000 due to any third party (other than, with respect to unsecured Indebtedness
only, payments contested by the Company and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect
to which adequate reserves have been set aside for the payment thereof in accordance with Generally Accepted Accounting Principles (GAAP))
or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $500,000, which breach or violation
permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other
circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default
under any agreement binding the Company or any Subsidiary, which default or event of default would or is likely to have a material adverse
effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition)
or prospects of the Company or any of its Subsidiaries, individually or in the aggregate;
(ix) the Company
or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to
Material Adverse Effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction
Document;
(x) a false or
inaccurate certification (including a false or inaccurate deemed certification) by the Company that either (A) the Equity Conditions are
satisfied, (B) there has been no Equity Conditions Failure, or (C) as to whether any Triggering Event has occurred;
(xi) any breach
or failure in any respect by the Company or any Subsidiary to comply with any provision of the covenants included in the Certificate of
Designations;
(xii) any Preferred
Shares remain outstanding on or after April 2, 2026;
(xiii) any Change
of Control occurs without the prior written consent of the Required Holders, which consent will not be unreasonably withheld, conditioned
or delayed;
(xiv) any Material
Adverse Effect occurs; or
(xv) any provision
of any Transaction Document will at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding
on or enforceable against the Company, or the validity or enforceability thereof is contested.
Conversion Price Adjustments
.
If on the ninetieth (90th) calendar day and one hundred eightieth (180) calendar day (each an "Adjustment Date") following
the occurrence of the later of (x) the date that Company stockholders approve the transaction and all securities issuable to the PIPE
Investors in connection therewith, as required by Nasdaq ("Stockholder Approval") and (y) the earlier of (a) the effective
date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series C Preferred
Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, as amended (the "Securities Act"),
the Conversion Price then in effect is greater than the Market Price then in effect (the "Adjustment Price"), the Conversion
Price will automatically lower to the Adjustment Price. As used herein, "Market Price" means, with respect to any Adjustment
Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on the Principal Market on any Trading Day
during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to such applicable Adjustment
Date (each, a "Market Price Measuring Period"). All such determinations to be appropriately adjusted for any stock dividend,
stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during
such applicable Market Price Measuring Period. Only downward adjustments will be made.
15
Share Combination Event
Adjustment
. In addition to the adjustments set forth above, if at any time and from time to time on or after Stockholder Approval,
there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the Common Stock
(each, a "Share Combination Event", and such date thereof, the "Share Combination Event Date") and the lowest
VWAP during the ten consecutive (10) Trading Day period ending and including the fifth (5) Trading Day immediately preceding the Share
Combination Event Date (the "Event Market Price") (provided if the Share Combination Event is effective after close of trading
on the primary Trading Market, then commencing on the next Trading Day which period will be the "Share Combination Adjustment Period")
is less than the Conversion Price then in effect, then at the close of trading on the primary Trading Market on the last day of the Share
Combination Adjustment Period, the Conversion Price then in effect on such fifth (5th) Trading Day will be reduced (but in no event increased)
to the Event Market Price, but not less than the Floor Price. Notwithstanding the foregoing, if one or more Share Combination Events occur
prior to Stockholder Approval being obtained and a reduction of the Conversion Price did not occur, once Stockholder Approval is obtained,
the Conversion Price will automatically be reduced to equal the lowest Event Market Price with respect to any Share Combination Event
that occurred prior to Stockholder Approval being obtained, but not less than the Floor Price.
Adjustments
for Dilutive Issuances or Variable Price Securities
. If and whenever the Company grants, issues or sells (or enters into any agreement
to grant, issue or sell), or pursuant to the provisions of the Certificate of Designations is deemed to have done any of the foregoing,
but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold, any shares of Common Stock
for a consideration price per share (the "New Issuance Price") less than a price equal to the Conversion Price in effect immediately
prior to such granting, issuance or sale (such Conversion Price then in effect is referred to herein as the "Applicable Price")
(the foregoing a "Dilutive Issuance"), then, immediately after such Dilutive Issuance, the Conversion Price then in effect
will be reduced to an amount equal to the New Issuance Price.
Additionally,
if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities that are issuable pursuant to
such agreement or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with
the market price of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, (each of the formulations for
such variable price being herein referred to as, the "Variable Price"), the holder shall have the right, but not the obligation,
in its sole discretion to substitute the Variable Price for the Conversion Price.
Voluntary
Adjustment Right
. Subject to the rules and regulations of the Principal Market, the Company has the right, at any time, with
the written consent of the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate
by the Company board of directors.
Change
of Control Exchange
. Upon a change of control of the Company, each holder may require the Company to exchange the holder's
shares of Series C Preferred Stock for consideration equal to the change of Control Election Price, to be satisfied at the Company's
election in either (x) cash or (y) rights convertible into such securities or other assets to which such holder would have been entitled
with respect to such shares of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate
event.
Fundamental
Transactions.
The Certificate of Designations prohibits the Company from entering specified fundamental transactions (including,
without limitation, mergers, business combinations and similar transactions) unless the Company (or the Company's successor) assumes
in writing all of the Company's obligations under the of Common Stock, except as provided in the transaction documents in the PIPE
Financing.
Redemption
Rights:
Optional
Redemption by the Company.
At any time, the Company has the right to redeem in cash all, but not less than all, of the Preferred
Shares then outstanding at a price (the "Company Optional Redemption Price") equal to 125% of the greater of (i) the Conversion
Amount being redeemed and (ii) the product of (1) the Conversion Rate with respect to the Conversion Amount being redeemed multiplied
by (2) the greatest closing sale price of the Company's Common Stock on any Trading Day during the period commencing on the date
immediately preceding the date the Company notifies the holders of its election to redeem and the date the Company makes the entire payment
required.
Mandatory Redemption by
the Company Upon a Bankruptcy Triggering Event.
Upon the occurrence and continuation of a Bankruptcy Triggering Event, the Company
will immediately redeem, in cash, each of the Preferred Shares then outstanding at a redemption price equal to the greater of (i) the
product of (A) the Conversion Amount to be redeemed multiplied by (B) 125% and (ii) the product of (X) the Conversion Rate with respect
to the Conversion Amount in effect immediately following the date of initial public announcement (or public filing of bankruptcy documents,
as applicable) of such Bankruptcy Triggering Event multiplied by (Y) the product of (1) 125% multiplied by (2) the greatest closing sale
price of the Common Stock on any Trading Day during the period commencing on the date immediately preceding such Bankruptcy Triggering
Event and ending on the date the Company pays the entire payment required, provided that a Holder may, in its sole discretion, waive such
right to receive payment upon a Bankruptcy Triggering Event, in whole or in part, and any such waiver will not affect any other rights
of such Holder or any other Holder hereunder, including any other rights in respect of such Bankruptcy Triggering Event or any right to
conversion (or Alternate Conversion), as applicable.
16
Voting
Rights
. The holders of the Series C Preferred Stock have no voting power and no right to vote on any matter at any time, either as
a separate series or class or together with any other series or class of share of capital stock, and are not entitled to call a meeting
of such holders for any purpose nor are they entitled to participate in any meeting of the holders of Common Stock, except as provided
in the Certificate of Designations (or as otherwise required by applicable law).
Covenants
.
The Certificate of Designations contains a variety of obligations on the Company's part not to engage in specified activities, which
are typical for transactions of this type. In particular, the Company will not, and will cause the Company's subsidiaries to not,
redeem, repurchase or declare any dividend or distribution on any of its capital stock (other than as required under the Certificate of
Designations). In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach or
default under the of Certificate of Designations or PIPE Warrants.
Ownership
Limitation.
In no event may any Preferred Shares be converted (or PIPE Warrants be exercised) and shares of Common Stock be issued
to any holder if after giving effect to the issuance of shares of Common Stock upon such conversion of the Preferred Shares (or exercise
of the PIPE Warrants), the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding shares
of Common Stock, which we refer to herein as the "
PIPE Blocker
"). The PIPE Blocker may be raised or lowered to any
other percentage not in excess of 9.99% at the option of the applicable holder of the Preferred Shares (or PIPE Warrants), except that
any raise will only be effective upon 61-days' prior notice to the Company.
Exchange
Right.
If the Company or any of its Subsidiaries consummates any Subsequent Placement (other than with respect to Excluded Securities
(as defined in the Securities Purchase Agreement)), and a holder elects in writing to the Company to participate in such Subsequent Placement,
each such holder may, at the option of such holder as elected in writing to the Company, exchange all, or any part, of the Preferred Shares
of such holder into the securities in such Subsequent Placement (with the aggregate amount of such securities to be issued in such exchange
equal to such aggregate amount of such securities with a purchase price valued at 120% of the Conversion Amount of the Preferred Shares
delivered by such holder in exchange therefor); provided that any such exchange will be subject to all applicable Nasdaq restrictions.
Reservation
Requirements.
So long as any Series C Preferred Stock remains outstanding, the Company will at all times reserve at least 150%
of the number of shares of Common Stock as will from time to time be necessary to effect the conversion of all Preferred Shares then outstanding.
Conditions
Precedent to Closing
: As set forth in the Securities Purchase Agreement, the obligations of each party to consummate the PIPE Financing
are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Committed
Equity Line of Credit ("ELOC"), described below under the caption "Common Stock Purchase Agreement".
17
PIPE Warrants
Exercise
Price
. The exercise price of the PIPE Warrants is $4.38, the Nasdaq Minimum Price (as defined below.) The exercise price is subject
to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares
of Common Stock issuable upon the exercise of the Warrant also will be adjusted so that the aggregate exercise price will be the same
immediately before and immediately after any such adjustment.
Exercise
Price Adjustments
. If on an Adjustment Date, the exercise price then in effect is greater than the Market Price then in effect (the
"Warrant Adjustment Price"), the exercise price will automatically lower to the Warrant Adjustment Price. As used herein,
"Market Price" means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest closing price
of the Common Stock on the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including, the Trading
Day ended immediately prior to such applicable Adjustment Date (each, a "Market Price Measuring Period"). All such determinations
to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately
decreases or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments will be made.
Adjustments
for Dilutive Issuances or Variable Price Securities
. If and whenever the Company grants, issues or sells (or enters into any agreement
to grant, issue or sell), or pursuant to the provisions of the Warrant is deemed to have done any of the foregoing, but excluding any
Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold any shares of Common Stock for a consideration
price per share (the "Warrant New Issuance Price") less than a price equal to the exercise price in effect immediately prior
to such granting, issuance or sale (the foregoing a "Warrant Dilutive Issuance"), then, immediately after such Warrant Dilutive
Issuance, the exercise price then in effect will be reduced to an amount equal to the Warrant New Issuance Price.
Additionally,
if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) securities at a Variable Price, the warrant
holder shall have the right, but not the obligation, in its sole discretion to exercise the PIPE Warrants at the Variable Price.
Exercise
Period
. The PIPE Warrants are exercisable beginning six months after the issuance date (the "Initial Exercisability Date")
and expiring on the third anniversary of the Initial Exercisability Date. The PIPE Warrants require "buy-in" payments to be
made by us for failure to deliver any shares of Common Stock issuable upon exercise.
Cashless
Exercise
. If at the time of exercise of the PIPE Warrants, there is no effective registration statement registering the shares of
the Company Common Stock underlying the PIPE Warrants, such PIPE Warrants may be exercised on a cashless basis pursuant to their terms.
Purchase
Rights; Participation Rights
. If the Company issues options, convertible securities, warrants, shares, or similar securities to holders
of the Company shares of the Company Common Stock, each Warrant holder has the right to acquire the same as if the holder had exercised
its Warrant. The holders of the PIPE Warrants are entitled to receive any dividends paid or distributions made to the holders of the Company's
shares of Common Stock on an "as if converted" basis.
Fundamental
Transactions
. The PIPE Warrants prohibit the Company from entering into specified fundamental transactions unless the successor entity
assumes all of the Company obligations under the PIPE Warrants under a written agreement before the transaction is completed. Upon specified
corporate events, a Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or
any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event
had the Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified changes
of control, a Warrant holder will have the right to force the Company to repurchase the holder's Warrant for a purchase price in
cash equal to the Black Scholes value, as calculated under the PIPE Warrants, of the then unexercised portion of the Warrant.
18
ELOC
Financing
On
October 2, 2024, the Company entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility with Keystone,
whereby the Company may offer and sell, from time to time at its sole discretion, and whereby Keystone has committed to purchase, up to
$25.0 million of the Company's newly issued Common Stock, subject to the limitations described below. Concurrently with entering
into the ELOC Purchase Agreement, the Company also entered into a registration rights agreement with Keystone, pursuant to which it agreed
to provide Keystone with certain registration rights related to the shares issued under the ELOC Purchase Agreement.
The
Company may, from time to time and at its sole discretion, direct Keystone to purchase shares of Common Stock upon the satisfaction of
certain conditions set forth in the Common Stock Purchase Agreement at a purchase price per share based on the market price of Common
Stock at the time of sale as computed under the ELOC Purchase Agreement. There is no upper limit on the price per share that Keystone
could be obligated to pay for Common Stock under the ELOC Purchase Agreement. The Company will control the timing and amount of any sales
of Common Stock to Keystone, and Keystone has no right to require the Company to sell any shares to it under the ELOC Purchase Agreement.
The
Company does not have a right to commence any sales of Common Stock to the Purchaser under the ELOC Purchase Agreement until the time
when all of the conditions to the Company's right to commence sales of Common Stock to the Purchaser set forth in the ELOC Purchase
Agreement have been satisfied, including that a registration statement covering the resale of such shares is declared effective by the
SEC and the final form of prospectus is filed with the SEC (the "Commencement Date"). Over the 36-month period from and after
the Commencement Date, the Company will control the timing and amount of any sales of Common Stock to the Purchaser. Actual sales of shares
of Common Stock to the Purchaser under the ELOC Purchase Agreement will depend on a variety of factors to be determined by the Company
from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the
appropriate sources of funding and the Company's operations.
Although the Purchase Agreement
provides that we may sell up to an aggregate of $25.0 million of our shares of our Common Stock to Keystone, only 6,250,000 shares of
our Common Stock (assuming the shares are sold at a price of $4.00 per share) are being registered for resale under the registration statement
that includes this prospectus. If it becomes necessary for us to issue and sell to Keystone under the Purchase Agreement more shares than
are being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $25.0 million under the Purchase
Agreement, we must first file with the SEC one or more additional registration statements to register under the Securities Act the resale
by Keystone of any such additional shares of our Common Stock we wish to sell from time to time under the Purchase Agreement, which the
SEC must declare effective, in each case, before we may elect to sell any additional shares of our Common Stock to Keystone under the
Purchase Agreement.
In
no event will the Company issue to the Purchaser under the ELOC Purchase Agreement more than 1,658,525 shares of Common Stock, representing
19.99% of the total number of shares of Common Stock outstanding immediately prior to the execution of the Common Stock Purchase Agreement,
unless (i) the Company obtains the approval of the issuance of such shares by its stockholders in accordance with the applicable stock
exchange rules or (ii) sales of Common Stock are made at a price equal to or in excess of the lower of (A) the closing price immediately
preceding the delivery of the applicable notice to the Purchaser and (B) the average of the closing prices of the Common Stock for the
five business days immediately preceding the delivery of such notice, such that the sales of such Common Stock to the Purchaser would
not count toward the Exchange Cap because they are "at market" under applicable stock exchange rules. On October 11, 2024
the Company obtained stockholder approval to issue shares to Keystone in excess of the Exchange Cap.
In
all cases, the Company may not issue or sell any shares of Common Stock to Keystone under the Common Stock Purchase Agreement which, when
aggregated with all other shares of Common Stock then beneficially owned by Keystone and its affiliates (as calculated pursuant to Section 13(d) of
the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder), would result in Keystone beneficially owning
more than 4.99% of the outstanding shares of Common Stock (the "ELOC Blocker").
At
any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is equal to or
greater than $0.05 (the "Purchase Date"), the Company may direct the Purchaser to purchase a specified number of shares
of Common Stock (a "Fixed Purchase") not to exceed 100,000 shares at a purchase price equal to the lesser of 90% of (i) the
daily volume weighted average price (the "VWAP") of the Common Stock for the five trading days immediately preceding the applicable
Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a share of Common Stock on the applicable Purchase Date for such
Fixed Purchase during the full trading day on such applicable Purchase Date. In any case, the Purchaser's commitment in any single
Fixed Purchase may not exceed $10,000.
19
In
addition, at any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is
equal to or greater than $0.05 and such business day is also the Purchase Date for a Fixed Purchase of an amount of shares of Common Stock
not less than the applicable Fixed Purchase Maximum Amount (as defined in the Common Stock Purchase Agreement) (the "VWAP Purchase
Date"), the Company may also direct the Purchaser to purchase, on the immediately following business day, an additional number of
shares of Common Stock in an amount up to the Maximum VWAP Purchase Amount (as defined in the Common Stock Purchase Agreement) (a "VWAP
Purchase") at a purchase price equal to the lesser of 90% of (i) the closing sale price of the Common Stock on the applicable VWAP
Purchase Date and (ii) the VWAP during the period on the applicable VWAP Purchase Date beginning at the opening of trading and ending
at the VWAP Purchase Termination Time (as defined in the Purchase Agreement). At any time from and after the Commencement Date, on any
business day that is also the VWAP Purchase Date for a VWAP Purchase, the Company may also direct the Purchaser to purchase, on such same
business day, an additional number of shares of Common Stock in an amount up to the Maximum Additional VWAP Purchase Amount (as defined
in the ELOC Purchase Agreement) (an "Additional VWAP Purchase") at a purchase price equal to the lesser of 90% of (i) the
closing sale price of the Common Stock on the applicable Additional VWAP Purchase Date and (ii) the VWAP during the Additional VWAP Purchase
Period (as defined in the Common Stock Purchase Agreement).
The
net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of
its Common Stock to Keystone. Pursuant to the ELOC Purchase Agreement, up to 30% of the proceeds from each Fixed Purchase and VWAP Purchase
Notice must be used to redeem shares of Series C Preferred Stock.
The
ELOC Purchase Agreement contains customary representations, warranties and agreements of the Company and Keystone, limitations and conditions
regarding sales of Common Stock, indemnification rights and other obligations of the parties.
There
are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the ELOC Purchase
Agreement other than a prohibition (with certain limited exceptions) on entering into a dilutive securities transaction during certain
periods when the Company is selling Common Stock to Keystone under the Purchase Agreement. Keystone has agreed that, during the term of
the Purchase Agreement, it will not engage in or effect, directly or indirectly, any short sales involving the Company's securities
or any hedging transaction that transfers the economic risk of ownership of the Common Stock.
The
Purchase Agreement will automatically terminate on the earliest to occur of (i) the expiration of the ELOC Registration Statement,
(ii) the date on which Keystone will have purchased from the Company under the ELOC Purchase Agreement an aggregate limit of shares
of Common Stock as defined therein, (iii) the date on which the Common Stock will have failed to be listed or quoted on Nasdaq or
another U.S. national securities exchange identified as an "eligible market" in the ELOC Purchase Agreement, (iv) the
30th trading day after the date on which a voluntary or involuntary bankruptcy proceeding involving the Company has been commenced that
is not discharged or dismissed prior to such trading day, and (v) the date on which a bankruptcy custodian is appointed for all or
substantially all of the Company's property or the Company makes a general assignment for the benefit of creditors. The Company
has the right to terminate the ELOC Purchase Agreement at any time after the Commencement Date (as defined in the ELOC Purchase Agreement),
at no cost or penalty, upon one trading day's prior written notice to Keystone. Keystone has the right to terminate the Purchase
Agreement upon ten trading days' prior written notice to the Company if certain specified events occur. The Company and Keystone
may also agree to terminate the ELOC Purchase Agreement by mutual written consent. Neither the Company nor Keystone may assign or transfer
the Company's respective rights and obligations under the ELOC Purchase Agreement.
Concurrent
with the execution of the ELOC Purchase Agreement, the Company entered into a registration rights agreement with Keystone (the "ELOC
Registration Rights Agreement"), pursuant to which the Company agreed to file a registration statement covering the issuance and
sale of the maximum number of shares issuable under the ELOC Purchase Agreement as may be permitted under applicable rules. The Company
agreed to use its commercially reasonable efforts to cause the registration statement to be filed within 45 days after the closing of
the ELOC Purchase Agreement and to have such registration statement effective within 120 days of such closing (or 90 days of such closing
if the Company is notified by the Securities and Exchange Commission that such registration statement will not be reviewed or subject
to further review).
20
Effect of Sales of our Common Stock under the ELOC Purchase Agreements
on our Stockholders
The Common Stock being registered for resale in
this offering may be issued and sold by us to the Selling Stockholder from time to time at our discretion, during the terms described
above. The resale by the Selling Stockholder of a significant quantity of shares registered for resale in this offering at any given time,
or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales
of our Common Stock, if any, to Keystone under the ELOC Purchase Agreement will be determined by us in our sole discretion, subject to
the satisfaction of certain conditions in the ELOC Purchase Agreement, and will depend upon market conditions and other factors. We may
ultimately decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant
to the ELOC Purchase Agreement. If we elect to sell Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has
acquired such shares, Keystone may resell all, some or none of such Common Stock at any time or from time to time in its discretion and
at different prices. As a result, investors who purchase Common Stock from Keystone in this offering at different times will likely pay
different prices for those shares of Common Stock, and so may experience different levels of dilution and in some cases substantial dilution
and different outcomes in their investment results. See "
Risk Factors
—
Risks Related to the Committed Equity Financings
—
Investors
who buy shares of Common Stock from Keystone at different times will likely pay different prices
."
Investors may experience a decline in the value
of the Common Stock they purchase from Keystone in this offering as a result of future sales made by us to Keystone at prices lower than
the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares of Common Stock
to Keystone under the Keystone ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales of Common Stock or
the mere existence of our arrangement with Keystone may make it more difficult for us to sell equity or equity-related securities in the
future at a time and at a price that we might otherwise wish to effect such sales.
Because the purchase price per share to be paid by Keystone for the
Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement, if any, will fluctuate based on the market prices
of our Common Stock at the time we make such election, as of the date of this prospectus, it is not possible for us to predict the number
of shares of Common Stock that we will sell to Keystone under the ELOC Purchase Agreement, the actual purchase price per share to be paid
by Keystone for those shares of Common Stock, or the actual gross proceeds to be raised by us from those sales, if any. As of October
30, 2024, there were 8,294,734 shares of Common Stock outstanding. If all of the 6,250,000 shares of our Common Stock offered for resale
by the Selling Stockholders under this prospectus were issued and outstanding as of October 30, 2024, such shares would represent approximately
42.97% of total number of shares of our Common Stock outstanding. The actual number of shares of our Common Stock issuable will vary depending
on the then current market price of shares of our Common Stock sold to the Selling Stockholder in this offering.
The number of shares of Common Stock ultimately
offered for sale by the Selling Stockholder for resale under this prospectus is dependent upon the number of shares of Common Stock, if
any, we ultimately sell to Keystone under the ELOC Purchase Agreement. Further, if and when we elect to sell shares of Common Stock to
Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone may resell all, some or none of such
shares of Common Stock at any time or from time to time in its discretion and at different prices.
The issuance of our shares of Common Stock to
the Selling Stockholder pursuant to the ELOC Purchase Agreement will not affect the rights or privileges of our existing stockholders,
except that the economic and voting interests of each of our existing stockholders will be diluted. Although the number of shares of Common
Stock that our existing stockholders own will not decrease, the shares of Common Stock owned by our existing stockholders will represent
a smaller percentage of our total outstanding shares of Common Stock after any such issuance.
21
Although the ELOC Purchase Agreement provides
that we may sell up to an aggregate of $25.0 million of shares of our Common Stock to Keystone, only 6,250,000 shares (assuming the shares
are sold at a price of $4.00 per share) are being registered for resale under the registration statement that includes this prospectus.
If it becomes necessary for us to issue and sell more shares than are being registered for resale under this prospectus in order to receive
aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must first file with the SEC one or more additional
registration statements to register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock
we wish to sell from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each case, before we may
elect to sell any additional shares of our Common Stock to Keystone under the ELOC Purchase Agreement.
The following table sets forth the number of shares of Common Stock
to be issued to Keystone under the ELOC Purchase Agreement registered hereunder at varying purchase prices:
Assumed Average
Purchase Price
Per Share
Number of Registered
Shares to be Issued if
Full Purchase
(1)
Percentage of
Outstanding Shares
After Giving Effect
to the Issuance to
Keystone
(2)
Gross Proceeds
from the Sale of Shares
to Keystone
Under the
Purchase
Agreement
$
2.00
12,500,000
33.33
%
$
25,000,000
$
2.96
(3)
8,445,946
25.25
%
$
25,000,000
$
4.00
6,250,000
20.00
%
$
25,000,000
$
7.50
3,333,333
11.76
%
$
25,000,000
$
10.00
2,500,000
9.09
%
$
25,000,000
Notes to table:
(1)
The purchase prices assume a discount to the market prices of
our shares, in accordance with the ELOC Purchase Agreement.
(2)
The denominator is based on 8,294,734 shares outstanding as of October
30, 2024, adjusted to include the number of shares set forth in the adjacent column that we would have sold to Keystone, assuming the
average purchase price in the first column. The numerator is based on the number of shares issuable pursuant to future sales under the
ELOC Purchase Agreement (that are the subject of this offering) at the corresponding assumed average purchase price set forth in the first
column.
(3)
The closing sale price of our Common Stock on October 30, 2024.
22
USE OF PROCEEDS
We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.
Pursuant to the ELOC Purchase
Agreement, 30% of the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of
the Company's Series C Preferred Stock.
Pursuant to the Amended and
Restated Forbearance Agreement, dated September 19, 2024, between the Company and Veru, we are required to pay to Veru 20% of the net
proceeds received from any sale of Common Stock under the ELOC Purchase Agreement during the to pay down our obligations to Veru.
Any proceeds we receive from
the sale of Common Stock under the ELOC Purchase Agreement, net of our obligations to Keystone and Veru, will be used for general corporate
and working capital or for other purposes that the Board, in its good faith, deems to be in the best interest of the Company. No assurances
can be given that we will receive any proceeds from sale of Common Stock under the ELOC Purchase Agreement.
23
DETERMINATION OF OFFERING PRICE
The Selling Stockholder will
offer Common Stock at the prevailing market prices or a privately negotiated price as it may determine from time to time.
The offering price of our
Common Stock to be sold by the Selling Stockholder does not necessarily bear any relationship to our book value, assets, past operating
results, financial condition, or any other established criteria of value. The facts considered in determining the offering price were
our financial condition and prospects, our limited operating history and the general condition of the securities market.
In addition, there is no
assurance that our Common Stock will trade at market prices in excess of the offering price as prices for our Common Stock in any public
market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.
24
DESCRIPTION OF CAPITAL STOCK
General
Our Amended and Restated
Certificate of Incorporation authorizes the issuance of up to 250,000,000 shares of Common Stock, $0.00001 par value per share, and 10,000,000
shares of preferred stock, $0.00001 par value per share. As of the date of this prospectus, we have 8,294,734 shares of Common Stock outstanding,
and 3,499 shares of Series C Preferred Stock issued and outstanding. Our shares of Common Stock are held of record by approximately 37
stockholders.
Common Stock
Our Common Stock is listed
on the Nasdaq Capital Market under the symbol "ONCO."
Under the terms of our Amended
and Restated Certificate of Incorporation, holders of our Common Stock are entitled to one vote for each share held on all matters submitted
to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares
of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times
and in such amounts as our Board from time to time may determine. Our Common Stock is not entitled to pre-emptive rights and is not subject
to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution
to stockholders are distributable ratably among the holders of our Common Stock after payment of liquidation preferences, if any, on any
outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of Common Stock are subject to and
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the
future.
Preferred Stock and Warrants
Under the terms of our Amended
and Restated Certificate of Incorporation, our Board is authorized, without further action by the stockholders, to establish one or more
class or series, and fix the relative rights and preferences of the company's undesignated capital stock.
For
the material terms of the Series C Preferred Stock and the PIPE Warrants, see "
PIPE Financing
."
Anti-Takeover Effects of Delaware Law and Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
Some provisions of Delaware
law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws could prohibit or delay mergers or other
takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer
our stockholders the opportunity to sell their stock at a price above the prevailing market price.
These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of the increased protection of
our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the
disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Delaware Anti-Takeover Statute
We are subject to Section
203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be "interested stockholders"
from engaging in a "business combination" with a publicly held Delaware corporation for three years following the date these
persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested
stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an "interested stockholder"
is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder
status did own, 15% or more of a corporation's voting stock. Generally, a "business combination" includes a merger,
asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision
may have an anti-takeover effect with respect to transactions not approved in advance by the Board.
25
Choice of Forum
Our Amended and Restated
Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, to the fullest extent permitted by law,
that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and certain
other actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A) as to which the Court of Chancery
in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and
the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination),
(B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C) for which the Court of Chancery
does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed
to have consented to service of process on such stockholder's counsel. Although we believe this provision benefits us by providing
increased consistency in the application of law in the types of lawsuits to which it applies, a court may determine that this provision
is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors
and officers.
Our Amended and Restated
Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable
law, subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce
any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision
will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent
in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce
this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section
22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder.
Transfer Agent and Registrar
The transfer agent and registrar
for our Common Stock is Continental Stock Transfer & Trust Company. The Transfer Agent's address is 1 State Street, 30
th
Floor, New York, New York 10004.
Listing
Our Common Stock is traded
on The Nasdaq Capital Market under the trading symbol "ONCO."
Elimination of Monetary Liability for Officers
and Directors
Our Amended and Restated
Certificate of Incorporation incorporates certain provisions permitted under the Delaware General Corporation Law ("DGCL")
relating to the liability of directors. The provisions eliminate a director's liability for monetary damages for a breach of fiduciary
duty, including gross negligence, except in circumstances involving certain wrongful acts, such as the breach of director's duty
of loyalty or acts or omissions, which involve intentional misconduct or a knowing violation of law. These provisions do not eliminate
a director's duty of care. Moreover, these provisions do not apply to claims against a director for certain violations of law, including
knowing violations of federal securities law. Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify
the directors, officers, employees or other agents to the fullest extent permitted by the DGCL. We believe that these provisions will
assist us in attracting and retaining qualified individual to serve as directors.
Indemnification of Officers and Directors
Our Amended and Restated
Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent
permitted by the DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect
monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions
will assist us in attracting or retaining qualified individuals to serve as our directors.
26
SELLING STOCKHOLDER
The shares of Common Stock
being offered by the Selling Stockholder are those previously issued to the Selling Stockholder, and those issuable to the Selling Stockholder
under the ELOC Purchase Agreement. We are registering the shares of Common Stock in order to permit the Selling Stockholder to offer the
shares for resale from time to time.
The table below lists the
Selling Stockholder and other information regarding the beneficial ownership of the shares of Common Stock by the Selling Stockholder.
The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder.
The third column lists
the shares of Common Stock being offered by this prospectus by the Selling Stockholder.
The fourth column assumes
the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.
Under the terms of the ELOC
Purchase Agreement, the Company may not issue shares to the Selling Stockholder under the ELOC Purchase Agreement to the extent that such
issuance would cause the Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares
of Common Stock which would exceed 4.99% of our then outstanding Common Stock following such issuance, excluding for purposes of such
determination shares of Common Stock issuable under the ELOC Purchase Agreement which have not been issued. The number of shares in the
second and fourth columns do not reflect this limitation.
The Selling Stockholder may
sell all, some or none of its shares in this offering. See "
Plan of Distribution
."
Name of Selling Shareholder
Number of
shares of
Common
Stock
Beneficially
Owned
Prior to
Offering
Percentage of
shares of
Common
Stock
Beneficially
Owned
Prior to
Offering
(1)
Maximum
Number of
shares of
Common
Stock
to be Sold
Pursuant to
this Prospectus
Number of
shares of
Common
Stock
Beneficially
Owned
After
Offering
Percentage of
shares of
Common
Stock
Beneficially
Owned
After
Offering
(1)
Keystone Capital Partners, LLC
435,646
(2)
4.99
%
6,250,000
435,646
2.91
%
(1)
Based on 8,294,734 shares outstanding as of October 30, 2024.
(2)
Represents shares of Common Stock underlying Series C Preferred
Stock held by this Selling Stockholder, after giving effect to the Maximum Percentage (as defined in the Series C Preferred Stock Certificate
of Designations). Keystone Capital Partners LLC is managed by RANZ Group LLC. Frederic Zaino, the Managing Member of RANZ Group LLC,
may be deemed to have investment discretion and voting power over the shares held by Keystone Capital Partners LLC. RANZ Group LLC and
Mr. Zaino each disclaim any beneficial ownership of these shares. The address of the selling stockholder is 139 Fulton Street, Suite
412, New York, NY 10038.
27
PLAN OF DISTRIBUTION
The Selling Stockholder of
the securities and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of its securities
covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following
methods when selling securities:
●
ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;
●
block trades in which the broker-dealer
will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;
●
purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;
●
an exchange distribution in
accordance with the rules of the applicable exchange;
●
privately negotiated transactions;
●
settlement of short sales;
●
in transactions through broker-dealers
that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;
●
through the writing or settlement
of options or other hedging transactions, whether through an options exchange or otherwise;
●
a combination of any such methods
of sale; or
●
any other method permitted
pursuant to applicable law.
The Selling Stockholder may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.
Broker-dealers engaged by
the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to
be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with Financial Industry Regulatory Authority ("FINRA") Rule 2121; and in the case of a
principal transaction a markup or markdown in compliance with FINRA Rule 2121.
Keystone Capital Partners, LLC has represented to us that at no time
prior to the date of the ELOC Purchase Agreement has such Selling Stockholder or its agents, representatives or affiliates engaged in
or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of
the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock.
Keystone Capital Partners, LLC has agreed that during the term of the ELOC Purchase Agreement, neither Keystone Capital Partners, LLC
nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.
28
The Selling Stockholder and
any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.
The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We have advised the Selling
Stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of
a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities
offered by this prospectus.
29
EXPERTS
The consolidated balance
sheet of Onconetix, Inc. and Subsidiary as of December 31, 2023, and the related consolidated statements of operations and comprehensive
loss, convertible redeemable preferred stock and stockholders' equity (deficit), and cash flows for the year then ended, have been
audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report, which report includes an explanatory
paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial
statements have been incorporated herein by reference in this prospectus in reliance on the report of such firm given upon their authority
as experts in accounting and auditing.
The consolidated financial
statements of Onconetix, Inc., formerly known as Blue Water Vaccines Inc., as of and for the year ended December 31, 2022, appearing in
the Company's Annual Report on Form 10-K for the year ended December 31, 2023, have been audited by CBIZ CPAs P.C. (formerly Mayer Hoffman
McCann, P.C.), independent registered public accounting firm, as set forth in their report, and have been incorporated herein by reference
in this prospectus in reliance upon such report given on the authority of such firm as experts in accounting and auditing, in giving said
reports.
The financial statements
of Proteomedix AG as of December 31, 2022, and 2021 and for each of the two years in the period ended December 31, 2022, which have been
incorporated by reference in this prospectus and the registration statement of which it forms a part, have been so included in reliance
on the report of BDO AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. The report on the financial statements contains an explanatory paragraph regarding Proteomedix AG's ability to continue
as a going concern. Such financial statements and audit report are incorporated by reference to the Company's Current Report on
Form 8-K/A, as filed with the SEC on February 27, 2024.
LEGAL MATTERS
Ellenoff Grossman & Schole
LLP, New York, New York, will pass upon the validity of the securities offered hereby.
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the informational
requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other
information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at
www.sec.gov
.
Copies of certain information filed by us with the SEC are also available on our website at
www.onconetix.com
. Our website is not
a part of this prospectus and is not incorporated by reference in this prospectus.
This prospectus is part of
a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance
with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about
us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed
as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements.
30
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to incorporate
by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring
you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part
of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated, and
those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you
must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any
document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents
listed below (File No. 000-52994) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial
registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement
until the offering of the securities under the registration statement is terminated or completed:
(i)
our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2023, as filed with the SEC on April 11, 2024
(ii)
our Quarterly Report on Form
10-Q for the quarter ended March 31, 2024, as filed with the SEC on
May 20, 2024
, and for the quarter ended June 30, 2024, as filed with
the SEC on
August 29, 2024
;
(iii)
Current Reports on Form 8-K
filed on each of
January 12, 2024
,
January 19, 2024
,
January 29, 2024
,
February 12, 2024
,
February 13, 2024
,
February 27, 2024
,
April 8, 2024
,
April 26, 2024
,
May 13, 2024
,
June 13, 2024
,
June 14, 2024
,
July 11, 2024
,
July 15, 2024
,
August 7, 2024
,
September 3, 2024
,
September 5, 2024
,
September 11, 2024
,
September 20, 2024
,
September 24, 2024
,
October 3, 2024
,
October 9, 2024
and
October 21, 2024
;
(iv)
our Definitive Proxy Statement,
as filed with the SEC on
August 1, 2024
, and the
supplemental proxy materials
filed with the SEC on September 3, 2024; and
(v)
the description of our securities
registered under Section 12 of the Exchange Act as filed as
Exhibit 4.2
on our Annual Report on
Form 10-K
for the year ended December
31, 2023, as filed with the SEC on April 11, 2024.
You may request a copy of
these filings, at no cost, by writing or telephoning us at the following address or telephone number:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
(513) 620-4101
You may also access the documents
incorporated by reference in this prospectus through our website at
www.onconetix.com
. Except for the specific incorporated documents
listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration
statement of which it forms a part. The information contained on our website is not part of this prospectus.
31
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
Set forth below are estimates
(except in the case of SEC registration fees) of the amount of fees and expenses to be incurred in connection with the issuance and distribution
of the offered securities, other than underwriting discounts and commissions.
SEC registration fee
$
2,884.98
Accounting services
37,500
Legal fees
37,500
*
Miscellaneous
5,000
*
Total
$
82,884.98
*
Estimated
Item 14. Indemnification of Directors and Officers.
Section 145 of the DGCL inter
alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that
such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys' fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding
if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized
for such persons against expenses (including attorneys' fees) actually and reasonably incurred in connection with the defense or
settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction
otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized
in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written
opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.
Section 145 further authorizes
a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or
not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers and
directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.
Section 102(b)(7) of the
DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of
a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such
provision shall not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the corporation
or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv) for
any transaction from which the director derived an improper personal benefit.
Article 6 of the bylaws of
the Company contains provisions which are designed to provide mandatory indemnification of directors and officers of the Company to the
full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the extent required by the
DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification will only be made upon
delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately
determined that such director is not entitled to indemnification.
II-
1
Item 16. Exhibits and Financial Statement Schedules.
Incorporated by Reference
Exhibit No.
Description
Form
Exhibit
Filing Date
2.1
Share Exchange Agreement, dated December 15, 2023, by and among the Company, Proteomedix, Thomas Meier and the Sellers.
8-K
2.1
December 21, 2023
3.1
Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February 23, 2022.
8-K
3.1
February 24. 2022
3.2
Certificate of Amendment to the Company's Second Amended and Restated Certificate of Incorporation
8-K
3.1
April 24, 2023
3.3
Certificate of Amendment to the Company's Second Amended and Restated Certificate of Incorporation.
8-K
3.1
December 21, 2023
3.4
Fourth Amended and Restated Bylaws of the Company.
8-K
3.2
December 21, 2023
3.5
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.
8-K
3.1
September 20, 2024
3.6
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.
8-K
3.1
September 24, 2024
4.1
Specimen Common Stock Certificate.
S-1
4.1
October 8, 2021
4.2
Description of Registered Securities.
10-K
4.2
April 11, 2024
4.3
Certificate of Designation of Series A Preferred Stock.
8-K
3.1
October 3, 2023
4.4
Certificate of Designation of Series B Convertible Preferred Stock.
8-K
4.1
December 21, 2023
4.5
Form of Inducement PIO.
8-K
4.1
August 3, 2023
4.6
Form of Inducement PIO.
8-K
4.1
July 11, 2024
4.7
Form of Altos Warrants.
8-K
4.1
September 24, 2024
4.8
Form of Warrant.
8-K
4.1
October 3, 2024
4.9
Certification of Designation of Series C Preferred Stock.
8-K
3.1
October 3, 2024
5.1**
Opinion of Ellenoff Grossman & Schole LLP as to the legality of the securities being registered.
10.1
2019 Equity Incentive Plan.
S-1
10.1
October 8, 2021
10.2
2022 Equity Incentive Plan.
S-1/A
10.2
November 29, 2021
10.3
2019 Equity Incentive Plan Form of Stock Option Grant Agreement.
S-1
10.3
October 8, 2021
10.4
2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).
S-1/A
10.4
January 6, 2022
10.5
2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).
S-1/A
10.5
January 6, 2022
10.6
2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).
S-1/A
10.6
January 6, 2022
10.7
2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).
S-1/A
10.7
January 6, 2022
10.8
Lease Agreement, dated as of April 29, 2021, between the Registrant and Regus Management Group, LLC.
S-1
10.11
October 8, 2021
10.9
Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of July 19, 2019.
S-1
10.12
October 8, 2021
II-
2
10.10
Project Addendum 1 to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of October 9, 2019.
S-1
10.13
October 8, 2021
10.11
Letter Agreement between the Registrant and Ology Bioservices, Inc., dated as of January 9, 2020.
S-1
10.14
October 8, 2021
10.12
Project Addendum II to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of May 21, 2021
S-1
10.15
October 8, 2021
10.13
Form of Employment Agreement with Joseph Hernandez
S-1
10.16
October 8, 2021
10.14
Form of Employment Agreement with Erin Henderson
S-1
10.17
October 8, 2021
10.15
Form of Employment Agreement with Jon Garfield.
S-1
10.18
October 8, 2021
10.16
Form of Employment Agreement with Neil Campbell.
8-K
10.1
October 10, 2023
10.17
Form of Employment Agreement with Bruce Harmon.
8-K
10.2
October 10, 2023
10.18
Form of Employment Agreement with Ralph Schiess.
10-K
10.21
April 11, 2024
10.19
Amendment to Employment Agreement, dated October 15, 2020, by and between Proteomedix and Ralph Schiess.
10-K
10.22
April 11, 2024
10.20
Amendment to Employment Agreement by and between Proteomedix and Ralph Schiess.
10-K
10.23
April 11, 2024
10.21
Form of Employment Agreement with Christian Brühlmann.
10-K
10.24
April 11, 2024
10.22
Amendment to Employment Agreement, dated October 16, 2020, by and between Proteomedix and Christian Brühlmann.
10-K
10.25
April 11, 2024
10.23
Amendment to Employment Agreement by and between Proteomedix and Christian Brühlmann.
10-K
10.26
April 11, 2024
10.24
General Release of Claims, dated October 5, 2023, by and between Jon Garfield and the Company.
8-K
99.1
October 10, 2023
10.25
Release, dated January 10, 2024, by and between the Company and Dr. Neil Campbell.
8-K
99.1
January 12, 2024
10.26
Form of Indemnification Agreement for Directors and Officers.
8-K
10.3
October 10, 2023
10.27
Form of Securities Purchase Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.
8-K
10.1
April 19, 2022
10.28
Form of Registration Rights Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.
8-K
10.2
April 19, 2022
10.29
Form of Securities Purchase Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.
8-K
10.1
August 11, 2022
10.30
Form of Registration Rights Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.
8-K
10.2
August 11, 2022
10.31
Settlement Agreement and Release, dated October 9, 2022, by and between the Registrant and Boustead Securities, LLC.
10-Q
10.3
November 14, 2022
10.32
Amendment No. 1 to Project Addendum 2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.
10-Q
10.1
May 13, 2022
II-
3
10.33
Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022, by and between the Registrant and St. Jude Children's Research Hospital, Inc.
10-Q
10.2
May 13, 2022
10.34
Patent & Technology License Agreement, dated November 18, 2022, between the Company and the University of Texas Health Science Center at San Antonio.
10-Q
10.1
May 12, 2023
10.35
Co-Development Agreement, dated February 1, 2023, between the Company and AbVacc, Inc.
10-Q
10.2
May 12, 2023
10.36
At-the-Market Offering Agreement, dated March 29, 2023, between the Company and H.C. Wainwright & Co., LLC.
8-K
1.1
March 29, 2023
10.37
Asset Purchase Agreement, dated April 19, 2023, between the Company and Veru Inc.
8-K
10.1
April 20, 2023
10.38
Amendment to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru Inc.
8-K
10.1
October 3, 2023
10.39
Form of Non-Competition and Non-Solicitation Agreement, dated April 19, 2023.
8-K
10.2
April 20, 2023
10.40
Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, and the Company.
8-K
10.1
June 14, 2023
10.41
Management Services Agreement, dated June 13, 2023, by and among WraSer, Xspire and the Company.
8-K
10.2
June 14, 2023
10.42
Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company.
10-Q
10.14
October 20, 2023
10.43
Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC.
10-Q
10.6
November 17, 2023
10.44
Form of Lock-Up Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.
8-K
10.1
December 21, 2023
10.45
Form of Non-Competition and Non-Solicitation Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.
8-K
10.2
December 21, 2023
10.46
Form of Stockholder Support Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and certain stockholders of Proteomedix
8-K
10.3
December 21, 2023
10.47
Form of Subscription Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and the PMX Investor.
8-K
10.4
December 21, 2023
10.48
Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson.
8-K
10.1
January 19, 2024
10.49
Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group.
8-K
10.2
January 19, 2024
10.50
Debenture, dated January 23, 2024 issued to the PMX Investor
8-K
10.1
January 29, 2024
10.51
Consulting Agreement, dated January 4, 2024, by and between the Company and Thomas Meier.
8-K
10.1
February 12, 2024
II-
4
10.52
License Agreement, dated March 27, 2023, between Proteomedix and Laboratory Corporation of America Holdings.
10-K
10.55
April 11, 2024
10.53
Form of Inducement Letter
8-K
10.1
August 1, 2023
10.54
Form of Letter Agreement.
8-K
10.1
August 3, 2023
10.55
Amendment to Debenture, dated April 24, 2024, issued to the PMX Investor.
8-K
10.2
April 26, 2024
10.56
Forbearance Agreement, dated April 24, 2024, by and between the Company and Veru Inc.
8-K
10.1
April 26, 2024
10.57
Master Research Services Agreement, dated October 1, 2022, by and between Proteomedix AG and Immunovia, AB
S-1/A
10.60
June 25, 2024
10.58
Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited
S-1/A
10.61
June 25, 2024
10.59
Amendment No. 1, dated June 26, 2023, to Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited
S-1/A
10.62
June 25, 2024
10.60
Release Agreement, dated June 10, 2024, between the Company and Bruce Harmon.
8-K
99.1
June 13, 2024
10.61
Consulting Agreement, dated June 10, 2024, between the Company and Karina Fedasz.
8-K/A
10.1
June 14, 2024
10.62
Form of Inducement Letter
8-K
10.1
July 11, 2024
10.63
Amended and Restated Forbearance Agreement between the Company and Veru, dated September 19, 2024
8-K
10.1
September 20, 2024
10.64
Form of Securities Purchase Agreement dated October 2, 2024 relating to the sale of the Series C Preferred Stock and Warrants
8-K
10.1
October 3, 2024
10.65
Form of Registration Rights Agreement dated as of October 2, 2024 relating to the resale of the shares of Common Stock underlying the Series C Preferred Stock and Warrants
8-K
10.2
October 3, 2024
10.66
Form of ELOC Purchase Agreement dated October 2, 2024
8-K
10.3
October 3, 2024
10.67
Form of ELOC Registration Rights Agreement dated October 2, 2024
8-K
10.4
October 3, 2024
16
Letter from EisnerAmper LLP, dated October 21, 2024.
8-K
6.1
October 21, 2024
21
List of Subsidiaries.
10-K
21
April 11, 2024
23.1*
Consent of CBIZ CPAs P.C.
23.1
23.2*
Consent of EisnerAmper LLP.
23.2
23.3*
Consent of BDO AG.
23.3
23.4**
Consent of Ellenoff Grossman & Schole (included as part of Exhibit 5.1 hereto).
24*
Power of Attorney (included on signature page to this Registration Statement).
107*
Filing Fee Table.
*
Filed herewith.
**
To be filed by amendment.
†
Certain of the exhibits and
schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of
all omitted exhibits and schedules to the SEC upon its request.
#
Certain portions of this exhibit
(indicated by "[*]" have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as we have determined they (1) are
not material and (2) are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy
of any omitted portion to the SEC upon request.
II-
5
Item 17. Undertakings.
The undersigned registrant
hereby undertakes:
(1)
That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(2)
To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(3)
That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser:
(i)
If the registrant is relying
on Rule 430B:
(A)
Each prospectus filed by the
registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and
(B)
Each prospectus required to
be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities
Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus.
As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such effective date; or
(ii)
If the registrant is subject
to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately prior to such date of first use.
Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
II-
6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Cincinnati, Ohio, on November  1, 2024.
ONCONETIX, INC.
By:
/s/ Karina M. Fedasz
Name:
Karina M. Fedasz
Title:
Interim Chief Financial Officer
KNOW ALL PERSONS BY THESE
PRESENTS that each individual whose signature appears below hereby constitutes and appoints each of Ralph Schiess and Karina M. Fedasz
as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place
and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement,
and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing
pursuant to Rule 462(b) promulgated under the Securities Act of 1933 increasing the number of shares for which registration is sought,
and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith,
making such changes in this registration statement as such attorney-in-fact and agent so acting deem appropriate, with the SEC, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to
be done with respect to the offering of securities contemplated by this registration statement, as fully to all intents and purposes as
he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his, her or their
substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and
on the dates indicated.
Signature
Title
Date
/s/ Ralph Schiess
Interim Chief Executive Officer
November  1, 2024
Ralph Schiess
(Principal Executive Officer)
/s/ Karina M. Fedasz
Interim Chief Financial Officer
November  1, 2024
Karina M. Fedasz
(Principal Financial and Accounting Officer)
/s/ James Sapirstein
Chairman of the Board and Director
November  1, 2024
James Sapirstein
/s/ Thomas Meier
Director
November 1, 2024
Thomas Meier
/s/ Timothy Ramdeen
Director
November  1, 2024
Timothy Ramdeen
/s/ Ajit Singh
Director
November 1, 2024
Ajit Singh
/s/ Simon Tarsh
Director
November  1, 2024
Simon Tarsh
II-7